ClinicalTrials.gg
CompletedNCT03084796GLIMMERUpdated Jun 15, 2021Results posted

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of CHF 5259 and Placebo in COPD and Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 112 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-06-15.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
733
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
17th of 73
733 · median 152
Started
2017
with 3 others
Phase 2
19 of 73
none open now
Registered
58th of 73
by date
Lead sponsor
13 of 73
Chiesi Farmaceutici S.p.A.

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 17th largest by enrollment, is one of 4 that started in 2017, is one of 19 in phase 2, and was the 58th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the dose-response of different doses of CHF 5259 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development in the target subject population.

Read the detailed description

This is a phase II, multicenter, randomized, double-blind, placebo and active controlled dose-ranging 6-arm parallel group study to identify the optimal dose of CHF 5259 pMDI (pressurized metered dose inhaler) with respect to lung function as well as other clinical efficacy and safety outcomes.

After a 2 week run-in period under rescue albuterol and background inhaled corticosteroid (ICS) as needed, patients were randomized to one of the 6 study treatment groups. Following randomization, subjects were assessed after 3 weeks and 6 weeks of study treatment at the study center. A follow-up phone was performed a week after the last visit.

During the study, daily symptoms, rescue and background medication use and compliance with the study drug were recorded in a subject diary. Treatment-Emergent Adverse Events (TEAEs) were assessed and recorded throughout the study. At screening and subsequent visits, subjects underwent physical and vital signs examinations, spirometry measurements, and 12-lead electrocardiogram (ECG). Symptoms and chronic obstructive pulmonary disease (COPD) health status were assessed through validated questionnaires. Routine hematology, blood chemistry, and pregnancy testing were performed before enrollment and at end of study. 24-hour (24-H) digital recording of ECGs (Holter) was performed before and after the first dose and just before the last dose of study treatment.

03

Conditions studied

  • COPD
  • Chronic Obstructive Pulmonary Disease

Keywords

  • CHF 5259
  • Chronic Obstructive Pulmonary Disease (COPD)
  • pMDI (pressurized metered dose inhaler)
  • GLIMMER
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged ≥ 40 who have signed an Form prior to initiation of any study-related procedure.
  • Subjects with a diagnosis of (according to GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD Report) at least 12 months before the screening visit.
  • Current smokers or ex-smokers who quit smoking at least 6 months prior to screening visit, with a smoking history of at least 10 pack years
  • A post-bronchodilator forced expiratory volume in the 1st second () ≥50% and \<80% of the predicted normal value and,
  • a post-bronchodilator FEV1/ Forced Vital Capacity (FVC) \< 0.7 at screening and
  • a demonstrated reversibility to ipratropium defined as ΔFEV1 ≥ 5% over baseline 30-45 minutes after inhaling 4 puffs of ipratropium
  • Subjects under regular COPD therapy for at least 2 months prior to screening with either inhaled long-acting muscarinic antagonist (LAMA), inhaled ICS/ long-acting β2-agonist (LABA), inhaled ICS + LAMA
  • Symptomatic subjects at screening with a CAT score ≥10. This criterion must be confirmed at randomization
  • Symptomatic subjects with a BDI focal score ≤ 10. This criterion must be confirmed at randomization
  • A cooperative attitude and ability to demonstrate correct use of the inhalers and e-diary.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women and all women physiologically capable of becoming pregnant UNLESS they are willing to use highly effective methods
  • Diagnosis of asthma or Asthma- Overlap Syndrome (ACOS) as described in global initiative for asthma (GINA) Report 2016, history of allergic rhinitis or atopy (atopy which may raise or impact the efficacy of the study treatment according to Investigator's judgment)
  • COPD Exacerbations: a moderate or severe COPD exacerbation that has not resolved ≤14 days prior to screening and ≤30 days following the last dose of any oral/systemic or antibiotic (whichever comes last). A Moderate or Severe COPD exacerbation during the run-in period
  • Use of antibiotics for a lower respiratory tract infection in the 4 weeks prior to screening or during run-in
  • Subjects treated with non-cardio-selective β-blockers in the month preceding screening or during the run-in period
  • Subjects treated with long-acting anti-histamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study, or if taken as needed
  • Subjects requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia
  • Known respiratory disorders other than COPD which may impact the efficacy of the study treatment according the Investigator's judgment.
  • Subjects who have cardiovascular condition
  • Subjects who have a clinically significant abnormal 12-lead that results in active medical problem which may impact the safety of the subject according to Investigator's judgement
  • Subjects whose 12-lead ECG shows Fridericia interval (QTcF) >450 ms for males or QTcF >470 ms for females at screening visit
  • Medical diagnosis of narrow-angle glaucoma, clinically relevant prostatic hypertrophy or bladder neck obstruction that in the opinion of the Investigator would prevent use of anticholinergic agents
  • History of to M3 receptor antagonists, β2-adrenergic receptor agonist, corticosteroids or any of the contained in any of the formulations used in the study which may raise contra-indications or impact the efficacy of the study treatment according to the Investigator's judgement
  • Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study treatment according to Investigator's judgement
  • Subjects with serum potassium levels \<3.5 mEq/L (or 3.5 mmol/L) at screening
  • Use of potent cytochrome P450 2D6 and 3A4 inhibitors within 4 weeks prior to screening
  • Unstable or uncontrolled concurrent disease; fever, endocrine disease, gastrointestinal disease; neurological disease; hematological disease; disorders, or other which may impact the feasibility of the results of the study according to Investigator's judgment
  • History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening
  • Subjects who have received an drug within 1 month or 5 half-lives (whichever is greater) prior to screening visit, or have been previously randomized in this trial, or are currently participating in another clinical trial.
  • Subjects who are mentally or legally incapacitated, or subjects accommodated in an establishment as a result of an official or judicial order.
  • Subjects who have undergone major surgery in the 3 months prior to screening visit or have a planned surgery during the trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
733 participants (actual)

Study arms

  • Experimental
    Treatment A

    CHF 5259 pMDI 6.25 μg, 1 inhalation twice daily (bid); (total daily dose \[TDD\] of CHF 5259 12.5 μg)

    Drug: CHF 5259

  • Experimental
    Treatment B

    CHF 5259 pMDI 12.5 μg, 1 inhalation bid; (TDD of CHF 5259: 25 μg)

    Drug: CHF 5259

  • Experimental
    Treatment C

    CHF 5259 pMDI 12.5 μg, 2 inhalations bid; (TDD of CHF 5259: 50 μg)

    Drug: CHF 5259

  • Experimental
    Treatment D

    CHF 5259 pMDI 25 μg, 2 inhalations bid; (TDD of CHF 5259: 100 μg)

    Drug: CHF 5259

  • Placebo comparator
    Treatment E

    Placebo, 2 inhalations of CHF 5259 pMDI-matched Placebo bid;

    Drug: Placebo

  • Active comparator
    Treatment F

    Tiotropium (TIO) 18 μg, SPIRIVA® HandiHaler®, 2 inhalations once daily (od) of the content of 1 capsule; (TDD of TIO: 18 μg)

    Drug: Tiotropium Bromide 18 µg Inhalation Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in FEV1 AUC(0-12h) Normalized by Time at Week 6

    Change from baseline in FEV1 AUC(0-12h), normalized by time, at the end of treatment (Week 6). Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 at Week 6 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (12 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-12h)=Mean FEV1 after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Change From Baseline in FEV1 AUC(0-12h) Normalized by Time on Day 1

    Change from baseline in FEV1 AUC(0-12h), normalized by time, on Day 1. Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 on Day 1 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (12 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-12h)=Mean FEV1 after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;

    Time frame: Baseline, Day 1

  2. Change From Baseline in FEV1 AUC(0-4h) Normalized by Time on Day 1 and at Week 6

    Change from baseline in FEV1 AUC(0-4h), normalized by time on Day 1 of treatment (Week 0). Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 on Day 1 and at Week 6 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-4h)=Mean FEV1 after inhalation, measured at prespecified times for up to 4-h observation period (0-4h), normalized by time;

    Time frame: Baseline, Day 1, Week 6

  3. Change From Baseline in FEV1 Peak(0-4h) at Day 1 and Week 6

    Change from baseline in FEV1 peak(0-4h) (L) on Day 1 and at Week 6. Peak FEV1 is defined as the maximum FEV1 observed in the first 4 hours after dose of study medication. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; Peak(0-4h)=Maximum FEV1 between 0 and 4 h.

    Time frame: Baseline, Day 1, Week 6

  4. Change From Baseline in FVC AUC(0-12h), Normalized by Time on Day 1 and at Week 6

    Change from baseline in FVC AUC(0-12h), normalized by time, on Day 1 and at the end of treatment (Week 6). Spirometry, used to measure FVC, was performed according to internationally accepted standards. The AUC for FVC was calculated by using the linear trapezoidal rule, based on the changes in FVC from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; FVC AUC(0-12h)=Mean FVC after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;

    Time frame: Baseline, Day 1, Week 6

  5. Change From Baseline in FVC AUC(0-4h) Normalized by Time on Day 1 and at Week 6

    Change from baseline in FVC AUC(0-4h), normalized by time, on Day 1 and at the end of treatment (Week 6). Spirometry, used to measure FVC, was performed according to internationally accepted standards. The AUC for FVC was calculated by using the linear trapezoidal rule, based on the changes in FVC from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; FVC AUC(0-4)=Mean FVC after inhalation, measured at prespecified times for up to 4-h observation period (0-4 h), normalized by time;

    Time frame: Baseline, Day 1, Week 6

  6. Change From Baseline in FVC Peak(0-4h) on Day 1 and at Week 6

    Change from baseline in FVC peak(0-4h) (L) on Day 1 and at the end of treatment at Week 6. Peak FEV1 is defined as the maximum FEV1 observed in the first 4 hours after dose of study medication. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; Peak(0-4h)=Maximum FEV1 between 0 and 4 h.

    Time frame: Baseline, Day 1, Week 6

  7. Time to Onset of Action (Change From Baseline in Post-dose FEV1 ≥ 100 mL) on Day 1

    Time to onset of action is defined as the time (in minutes) from receiving the study drug on Day 1, until the FEV1 change from baseline is ≥100 mL.

    Time frame: Day 1

  8. Number of Patients Achieving Onset of Action - Change From Baseline in Post-dose FEV1 ≥100 mL on Day 1

    Number of patients achieving onset of action was defined as a change from baseline in post-dose FEV1 ≥100 mL on Day 1. These are the patients who contributed to the results, reported as median and 95% CI for 'time to onset of action' presented in Outcome Measure 8, above.

    Time frame: Day 1

  9. Change From Baseline in Pre-dose Morning FEV1 at Week 3 and Week 6

    Change from baseline in FEV1 at treatment visit 3 (Week 3) and treatment visit 4 (Week 6) of treatment. Spirometry, used to measure FEV1, was performed according to internationally accepted standards. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second;

    Time frame: Baseline, Week 3, Week 6

  10. Change From Baseline in Pre-Dose Morning Inspiratory Capacity (IC) at Week 3 and Week 6

    Change from baseline in IC at treatment Visit 3 (Week 3) and treatment Visit 4 (Week 6). Spirometry was used to measure IC and was performed according to internationally accepted standards. Definitions: Baseline: value of the measurement recorded at 45 mins pre-dose at Visit 2 (Week 0); IC=Inspiratory capacity;

    Time frame: Baseline, Week 3, Week 6

  11. Transition Dyspnea Index (TDI) Response (Focal Score ≥1) at Week 3 and Week 6

    Number of subjects achieving TDI focal score ≥1, at treatment visit 3 (Week 3) and at treatment visit 4 (Week 6). TDI is a validated, interviewer-administered questionnaire that measures changes in dyspnea severity from the baseline established by the BDI questionnaire. TDI consists of the same 24 items and 3 domains as the BDI, with the same 2-week recall period. Each category is rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement); total score ranging from -9 to +9, with higher scores indicating better outcomes. The minimal clinically important differences (MCID) is considered a change of ≥1 unit. The same investigator or designee interviewed the subject for the BDI and TDI during the study period. A TDI focal score of ≥1 is considered as clinically important. Definitions: Baseline=The BDI focal score value at Visit 2 (Week 0); BDI=Baseline Dyspnea Index; MCID=Minimal Clinically Important Differences; TDI=Transition Dyspnea Index;

    Time frame: Baseline, Week 3, Week 6

  12. Transition Dyspnea Index (TDI) Focal Score at Week 3 and Week 6

    Transitional Dyspnea Index (TDI) focal score at treatment visit 3 (Week 3) and treatment visit 4 (Week 6). TDI is a validated, interviewer-administered questionnaire that measures changes in dyspnea severity from the baseline established by the BDI questionnaire. TDI consists of the same 24 items and 3 domains as the BDI, with the same 2-week recall period. Each category is rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement), with a total score ranging from -9 to +9, with higher scores indicating better outcomes. The minimal clinically important differences (MCID) is considered a change of ≥1 unit. The same investigator or designee interviewed the subject for the BDI and TDI during the study period. A TDI focal score of ≥1 is considered as clinically important. Definitions: Baseline=The BDI focal score value at Visit 2 (Week 0); BDI=Baseline Dyspnea Index; MCID=Minimal Clinically Important Differences; TDI=Transition Dyspnea Index;

    Time frame: Baseline, Week 3, Week 6

  13. Change From Baseline in Percentage of Rescue Medication-Free Days During Inter-Visit Periods and the Entire Treatment Period

    Evaluate the number of rescue medication-free days compared with baseline. Results are shown as percentage (%) of rescue medication-free days; an increased value indicates improvement from baseline. Definitions: Baseline=Data recorded during the run-in period (a 2-week period prior to randomization to study treatment and study drug intake); Inter-visit period 1=Starts at randomization to treatment (Visit 2, Week 0) and runs to the day before the subject returns to the clinic (Visit 3, Week 3); Inter-visit period 2=Starts when the subject returns to the clinic (Visit 3, Week 3) and runs to the end of the randomized treatment period (Visit 4, Week 6); Entire Treatment period=From day of randomization to drug intake to the end of the randomized treatment period (Visit 4, Week 6); Randomization=Randomization to study drug treatment (Visit 2, Week 0).

    Time frame: Baseline, Inter-visit period 1, Inter-visit period 2, Entire treatment period

  14. Change From Baseline in Average Use of Rescue Medication During Inter-Visit Periods and the Entire Treatment Period

    Evaluate the change from baseline in average use of rescue medication (number of puffs/day) during the inter-visit periods and the entire treatment period. Results are shown as number of puffs/day; a decrease (implies improvement) from baseline in average use of rescue medication. Definitions: Baseline=Data recorded during the run-in period (a 2-week period prior to randomization to study treatment and study drug intake); Inter-visit period 1=Starts at randomization to treatment (Visit 2, Week 0) and runs to the day before the subject returns to the clinic (Visit 3 (Week 3); Inter-visit period 2=Starts when the subject returns to the clinic (Visit 3, Week 3) and runs to the end of the randomized treatment period (Visit 4, Week 6); Entire Treatment period=From day of randomization to drug intake to the end of the randomized treatment period (Visit 4, Week 6); Randomization=Randomization to study drug treatment (Visit 2, Week 0);

    Time frame: Baseline, Inter-visit period 1, Inter-visit period 2, Entire treatment period

  15. Change From Baseline in Average EXACT-Respiratory Symptom (E-RS) Total Score During Inter-Visit Periods and the Entire Treatment Period

    Change from baseline in average EXACT-Respiratory Symptom (E-RS) total score during inter-visit periods and the entire treatment period E-RS in COPD uses 11 respiratory symptom items from the 14-item EXAcerbations of COPD tool (EXACT). E-RS total score quantifies respiratory symptom severity on a scale ranging from 0 to 40. Higher E-RS total scores indicate more severe symptoms and a declining total score indicates health improvement. E-RS questionnaire was completed by the patient each evening (e-diary). Definitions: For details on baseline, inter-visit periods, and the entire treatment period, please refer to outcome measure #15.

    Time frame: Baseline, Inter-visit period 1, Inter-visit period 2, Entire treatment period

  16. Vital Signs -- Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)

    Vital signs -- Systolic blood pressure (SBP), Diastolic blood pressure (DBP) were measured at prespecified times, using a 12-Lead single ECGs were recorded at all study visits (pre-dose at V1 (Week -2) and V3 (Week 3), as well as at pre-dose and 1.5 hours post-dose at Visit 2 (Week 0) and Visit 4 (Week 6). Results are shown by treatment group, as change from baseline (in mmHg) for representative timepoints. Definitions: Baseline=Values recorded pre-dose (Visit 2, Week 0); Day 1=Day of the first dose of randomized study drug (Visit 2, Week 0);

    Time frame: Baseline, Day 1, Week 6

  17. Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - Heart Rate (HR)

    Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - Heart rate (HR) Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5m, +55m, and at +2.5 h.

    Time frame: Baseline, Day 1, Week 6

  18. Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - PR Interval

    Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - PR Interval Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values were recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.

    Time frame: Baseline, Day 1, Week 6

  19. Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - QRS Interval

    Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - QRS Interval Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values were recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.

    Time frame: Baseline, Day 1, Week 6

  20. Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - Fridericia-corrected QT Interval (QTcF)

    Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - Fridericia-corrected QT interval (QTcF). Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.

    Time frame: Baseline, Day 1, Week 6

  21. 24-hour Holter ECG - Prolonged QTcF - Male Subjects

    24-hour Holter ECG - Prolonged QTcF - Male subjects. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.

    Time frame: Baseline, Day 1, Week 6

  22. 24-hour Holter ECG - Prolonged QTcF - Female Subjects

    24-hour Holter ECG - Prolonged QTcF - Female subjects. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.

    Time frame: Baseline, Day 1, Week 6

  23. 24-hour Holter ECG - Prolonged QTcF - Change From Baseline

    24-hour Holter ECG - Prolonged QTcF - Change from baseline. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h. Results are presented as the number of subjects who had a change from baseline in QTcF of: \> 30 msec, \> 60 msec, and no prolongation (by \> 30 msec or \> 60 msec).

    Time frame: Baseline, Day 1, Week 6

07

Results

Posted Jun 15, 2021

Participant flow

Participant flow — Overall Study
MilestoneTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Started121123122123121123
Completed114113110119110116
Not completed710124117
Withdrew: Adverse event456235
Withdrew: Withdrawal by subject352130
Withdrew: Protocol violation001011
Withdrew: Lack of efficacy001010
Withdrew: Lost to follow-up001131
Withdrew: Randomization error001000

Outcome measures

PrimaryChange From Baseline in FEV1 AUC(0-12h) Normalized by Time at Week 6

Change from baseline in FEV1 AUC(0-12h), normalized by time, at the end of treatment (Week 6). Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 at Week 6 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (12 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-12h)=Mean FEV1 after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;

Time frame:
Baseline, Week 6
Reported as:
Least squares mean · Litres
Change From Baseline in FEV1 AUC(0-12h) Normalized by Time at Week 6
LitresTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Change From Baseline in FEV1 AUC(0-12h) Normalized by Time at Week 60.070 (0.034 to 0.106)0.118 (0.082 to 0.155)0.153 (0.116 to 0.190)0.147 (0.111 to 0.183)0.002 (-0.035 to 0.039)0.213 (0.177 to 0.250)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.037 · Mean difference (final values): 0.068 · 95% CI 0.003 to 0.132
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.116 · 95% CI 0.051 to 0.181
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.151 · 95% CI 0.086 to 0.216
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.145 · 95% CI 0.081 to 0.209
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.211 · 95% CI 0.159 to 0.263
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.066 · Mean difference (final values): 0.048 · 95% CI -0.003 to 0.100
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.002 · Mean difference (final values): 0.083 · 95% CI 0.031 to 0.135
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 0.077 · 95% CI 0.026 to 0.128
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.189 · Mean difference (final values): 0.035 · 95% CI -0.017 to 0.087
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.273 · Mean difference (final values): 0.029 · 95% CI -0.023 to 0.080
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.813 · Mean difference (final values): -0.006 · 95% CI -0.058 to 0.045
SecondaryChange From Baseline in FEV1 AUC(0-12h) Normalized by Time on Day 1

Change from baseline in FEV1 AUC(0-12h), normalized by time, on Day 1. Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 on Day 1 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (12 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-12h)=Mean FEV1 after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;

Time frame:
Baseline, Day 1
Reported as:
Least squares mean · Litres
Change From Baseline in FEV1 AUC(0-12h) Normalized by Time on Day 1
LitresTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Change From Baseline in FEV1 AUC(0-12h) Normalized by Time on Day 10.067 (0.041 to 0.093)0.086 (0.060 to 0.111)0.135 (0.109 to 0.161)0.149 (0.123 to 0.175)0.009 (-0.017 to 0.035)0.192 (0.166 to 0.218)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.002 · Mean difference (final values): 0.059 · 95% CI 0.022 to 0.095
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.077 · 95% CI 0.040 to 0.113
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.126 · 95% CI 0.089 to 0.163
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.140 · 95% CI 0.104 to 0.177
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.183 · 95% CI 0.147 to 0.220
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.322 · Mean difference (final values): 0.018 · 95% CI -0.018 to 0.055
  • Treatment A vs Treatment C · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.067 · 95% CI 0.031 to 0.104
  • Treatment A vs Treatment D · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.082 · 95% CI 0.045 to 0.118
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.008 · Mean difference (final values): 0.049 · 95% CI 0.013 to 0.086
  • Treatment B vs Treatment D · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.063 · 95% CI 0.027 to 0.100
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.443 · Mean difference (final values): 0.014 · 95% CI -0.022 to 0.051
SecondaryChange From Baseline in FEV1 AUC(0-4h) Normalized by Time on Day 1 and at Week 6

Change from baseline in FEV1 AUC(0-4h), normalized by time on Day 1 of treatment (Week 0). Spirometry, used to measure FEV1, was performed according to internationally accepted standards. The AUC for FEV1 on Day 1 and at Week 6 of treatment was calculated by using the linear trapezoidal rule, based on the changes in FEV1 from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; FEV1 AUC(0-4h)=Mean FEV1 after inhalation, measured at prespecified times for up to 4-h observation period (0-4h), normalized by time;

Time frame:
Baseline, Day 1, Week 6
Reported as:
Least squares mean · Litres
Change From Baseline in FEV1 AUC(0-4h) Normalized by Time on Day 1 and at Week 6
LitresTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Day 10.101 (0.077 to 0.125)0.115 (0.091 to 0.139)0.173 (0.149 to 0.196)0.190 (0.166 to 0.214)0.030 (0.006 to 0.053)0.194 (0.170 to 0.218)
Week 60.116 (0.078 to 0.154)0.157 (0.118 to 0.195)0.198 (0.159 to 0.237)0.204 (0.167 to 0.242)0.024 (-0.015 to 0.062)0.253 (0.215 to 0.291)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.072 · 95% CI 0.038 to 0.105
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.086 · 95% CI 0.052 to 0.119
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.143 · 95% CI 0.109 to 0.177
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.160 · 95% CI 0.127 to 0.194
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.164 · 95% CI 0.131 to 0.198
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.418 · Mean difference (final values): 0.014 · 95% CI -0.020 to 0.048
  • Treatment A vs Treatment C · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.071 · 95% CI 0.038 to 0.105
  • Treatment A vs Treatment D · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.089 · 95% CI 0.055 to 0.122
  • Treatment B vs Treatment C · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.057 · 95% CI 0.024 to 0.091
  • Treatment B vs Treatment D · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.075 · 95% CI 0.041 to 0.108
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.308 · Mean difference (final values): 0.017 · 95% CI -0.016 to 0.051
  • Treatment A vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.092 · 95% CI 0.038 to 0.147
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.133 · 95% CI 0.079 to 0.188
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.174 · 95% CI 0.120 to 0.229
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.181 · 95% CI 0.127 to 0.235
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.229 · 95% CI 0.175 to 0.284
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.141 · Mean difference (final values): 0.041 · 95% CI -0.013 to 0.095
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 0.082 · 95% CI 0.028 to 0.137
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.001 · Mean difference (final values): 0.088 · 95% CI 0.035 to 0.142
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.137 · Mean difference (final values): 0.041 · 95% CI -0.013 to 0.096
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.082 · Mean difference (final values): 0.048 · 95% CI -0.006 to 0.101
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.823 · Mean difference (final values): 0.006 · 95% CI -0.048 to 0.060
SecondaryChange From Baseline in FEV1 Peak(0-4h) at Day 1 and Week 6

Change from baseline in FEV1 peak(0-4h) (L) on Day 1 and at Week 6. Peak FEV1 is defined as the maximum FEV1 observed in the first 4 hours after dose of study medication. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second; Peak(0-4h)=Maximum FEV1 between 0 and 4 h.

Time frame:
Baseline, Day 1, Week 6
Reported as:
Least squares mean · Litres
Change From Baseline in FEV1 Peak(0-4h) at Day 1 and Week 6
LitresTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Day 10.197 (0.170 to 0.224)0.211 (0.183 to 0.238)0.260 (0.233 to 0.287)0.288 (0.261 to 0.315)0.136 (0.109 to 0.163)0.299 (0.272 to 0.326)
Week 60.212 (0.171 to 0.253)0.255 (0.214 to 0.296)0.305 (0.263 to 0.346)0.301 (0.260 to 0.341)0.143 (0.102 to 0.185)0.356 (0.315 to 0.397)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.002 · Mean difference (final values): 0.061 · 95% CI 0.022 to 0.100
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.075 · 95% CI 0.036 to 0.113
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.124 · 95% CI 0.085 to 0.163
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.152 · 95% CI 0.113 to 0.190
  • Treatment E vs Treatment F · MMRM · p = <0.001 · Mean difference (final values): 0.163 · 95% CI 0.124 to 0.202
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.485 · Mean difference (final values): 0.014 · 95% CI -0.025 to 0.052
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.001 · Mean difference (final values): 0.063 · 95% CI 0.025 to 0.102
  • Treatment A vs Treatment D · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.091 · 95% CI 0.053 to 0.130
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.012 · Mean difference (final values): 0.050 · 95% CI 0.011 to 0.088
  • Treatment B vs Treatment D · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.077 · 95% CI 0.039 to 0.116
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.157 · Mean difference (final values): 0.028 · 95% CI -0.011 to 0.066
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.021 · Mean difference (final values): 0.069 · 95% CI 0.011 to 0.128
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.112 · 95% CI 0.053 to 0.170
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.162 · 95% CI 0.103 to 0.220
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.157 · 95% CI 0.099 to 0.215
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.213 · 95% CI 0.154 to 0.271
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.149 · Mean difference (final values): 0.043 · 95% CI -0.015 to 0.101
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.002 · Mean difference (final values): 0.092 · 95% CI 0.034 to 0.151
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 0.088 · 95% CI 0.031 to 0.146
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.096 · Mean difference (final values): 0.050 · 95% CI -0.009 to 0.108
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.122 · Mean difference (final values): 0.045 · 95% CI -0.012 to 0.103
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.886 · Mean difference (final values): -0.004 · 95% CI -0.062 to 0.054
SecondaryChange From Baseline in FVC AUC(0-12h), Normalized by Time on Day 1 and at Week 6

Change from baseline in FVC AUC(0-12h), normalized by time, on Day 1 and at the end of treatment (Week 6). Spirometry, used to measure FVC, was performed according to internationally accepted standards. The AUC for FVC was calculated by using the linear trapezoidal rule, based on the changes in FVC from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; FVC AUC(0-12h)=Mean FVC after inhalation, measured at prespecified times for up to 12-h observation period (0-12 h), normalized by time;

Time frame:
Baseline, Day 1, Week 6
Reported as:
Least squares mean · Litres
Change From Baseline in FVC AUC(0-12h), Normalized by Time on Day 1 and at Week 6
LitresTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Day 10.086 (0.039 to 0.133)0.133 (0.086 to 0.180)0.195 (0.148 to 0.242)0.220 (0.173 to 0.267)0.011 (-0.036 to 0.058)0.305 (0.258 to 0.351)
Week 60.084 (0.026 to 0.142)0.145 (0.087 to 0.203)0.190 (0.131 to 0.249)0.184 (0.127 to 0.241)-0.029 (-0.087 to 0.030)0.298 (0.240 to 0.355)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.029 · Mean difference (final values): 0.074 · 95% CI 0.008 to 0.141
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.121 · 95% CI 0.055 to 0.188
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.184 · 95% CI 0.117 to 0.250
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.208 · 95% CI 0.142 to 0.275
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.293 · 95% CI 0.227 to 0.360
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.161 · Mean difference (final values): 0.047 · 95% CI -0.019 to 0.113
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.001 · Mean difference (final values): 0.109 · 95% CI 0.043 to 0.176
  • Treatment A vs Treatment D · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.134 · 95% CI 0.068 to 0.201
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.066 · Mean difference (final values): 0.062 · 95% CI -0.004 to 0.128
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.010 · Mean difference (final values): 0.087 · 95% CI 0.021 to 0.153
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.465 · Mean difference (final values): 0.025 · 95% CI -0.042 to 0.091
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.008 · Mean difference (final values): 0.112 · 95% CI 0.030 to 0.195
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.173 · 95% CI 0.091 to 0.256
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.219 · 95% CI 0.136 to 0.302
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.213 · 95% CI 0.131 to 0.295
  • Treatment E vs Treatment F · McNemar · p = <0.001 · Mean difference (final values): 0.326 · 95% CI 0.244 to 0.409
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.144 · Mean difference (final values): 0.061 · 95% CI -0.021 to 0.143
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.011 · Mean difference (final values): 0.107 · 95% CI 0.024 to 0.189
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.016 · Mean difference (final values): 0.101 · 95% CI 0.019 to 0.182
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.280 · Mean difference (final values): 0.045 · 95% CI -0.037 to 0.128
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.342 · Mean difference (final values): 0.039 · 95% CI -0.042 to 0.121
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.886 · Mean difference (final values): -0.006 · 95% CI -0.088 to 0.076
SecondaryChange From Baseline in FVC AUC(0-4h) Normalized by Time on Day 1 and at Week 6

Change from baseline in FVC AUC(0-4h), normalized by time, on Day 1 and at the end of treatment (Week 6). Spirometry, used to measure FVC, was performed according to internationally accepted standards. The AUC for FVC was calculated by using the linear trapezoidal rule, based on the changes in FVC from the baseline values, and divided by the observation time (4 hours). Definitions: AUC=Area under the curve; Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; FVC AUC(0-4)=Mean FVC after inhalation, measured at prespecified times for up to 4-h observation period (0-4 h), normalized by time;

Time frame:
Baseline, Day 1, Week 6
Reported as:
Least squares mean · Litres
Change From Baseline in FVC AUC(0-4h) Normalized by Time on Day 1 and at Week 6
LitresTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Day 10.133 (0.087 to 0.179)0.192 (0.146 to 0.238)0.244 (0.198 to 0.290)0.273 (0.227 to 0.319)0.036 (-0.010 to 0.082)0.311 (0.266 to 0.357)
Week 60.149 (0.089 to 0.210)0.203 (0.143 to 0.264)0.248 (0.187 to 0.309)0.253 (0.194 to 0.313)0.000 (-0.062 to 0.061)0.353 (0.293 to 0.413)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 0.097 · 95% CI 0.032 to 0.163
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.156 · 95% CI 0.091 to 0.221
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.208 · 95% CI 0.143 to 0.273
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.237 · 95% CI 0.172 to 0.302
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.276 · 95% CI 0.211 to 0.341
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.076 · Mean difference (final values): 0.059 · 95% CI -0.006 to 0.124
  • Treatment A vs Treatment C · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.111 · 95% CI 0.046 to 0.176
  • Treatment A vs Treatment D · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.140 · 95% CI 0.075 to 0.205
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.116 · Mean difference (final values): 0.052 · 95% CI -0.013 to 0.117
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.014 · Mean difference (final values): 0.081 · 95% CI 0.016 to 0.146
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.384 · Mean difference (final values): 0.029 · 95% CI -0.036 to 0.094
  • Treatment A vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.150 · 95% CI 0.064 to 0.236
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.204 · 95% CI 0.118 to 0.290
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.248 · 95% CI 0.162 to 0.335
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.254 · 95% CI 0.168 to 0.339
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.354 · 95% CI 0.268 to 0.439
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.214 · Mean difference (final values): 0.054 · 95% CI -0.031 to 0.140
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.025 · Mean difference (final values): 0.098 · 95% CI 0.012 to 0.184
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.016 · Mean difference (final values): 0.104 · 95% CI 0.019 to 0.189
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.313 · Mean difference (final values): 0.044 · 95% CI -0.042 to 0.130
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.250 · Mean difference (final values): 0.050 · 95% CI -0.035 to 0.135
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.898 · Mean difference (final values): 0.006 · 95% CI -0.080 to 0.091
SecondaryChange From Baseline in FVC Peak(0-4h) on Day 1 and at Week 6

Change from baseline in FVC peak(0-4h) (L) on Day 1 and at the end of treatment at Week 6. Peak FEV1 is defined as the maximum FEV1 observed in the first 4 hours after dose of study medication. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); Day 1=Day of the first dose of randomized study drug at Visit 2 (Week 0); FVC=Forced Vital Capacity; Peak(0-4h)=Maximum FEV1 between 0 and 4 h.

Time frame:
Baseline, Day 1, Week 6
Reported as:
Least squares mean · Litres
Change From Baseline in FVC Peak(0-4h) on Day 1 and at Week 6
LitresTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Day 10.293 (0.241 to 0.345)0.372 (0.320 to 0.423)0.414 (0.362 to 0.466)0.455 (0.403 to 0.506)0.213 (0.161 to 0.266)0.491 (0.439 to 0.542)
Week 60.322 (0.258 to 0.386)0.379 (0.315 to 0.443)0.431 (0.366 to 0.495)0.427 (0.364 to 0.490)0.182 (0.117 to 0.247)0.530 (0.467 to 0.594)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.035 · Mean difference (final values): 0.079 · 95% CI 0.006 to 0.153
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.158 · 95% CI 0.085 to 0.232
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.201 · 95% CI 0.127 to 0.275
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.241 · 95% CI 0.168 to 0.315
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.277 · 95% CI 0.204 to 0.351
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.035 · Mean difference (final values): 0.079 · 95% CI 0.005 to 0.152
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.001 · Mean difference (final values): 0.121 · 95% CI 0.048 to 0.195
  • Treatment A vs Treatment D · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.162 · 95% CI 0.088 to 0.235
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.256 · Mean difference (final values): 0.043 · 95% CI -0.031 to 0.116
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.027 · Mean difference (final values): 0.083 · 95% CI 0.010 to 0.156
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.281 · Mean difference (final values): 0.040 · 95% CI -0.033 to 0.114
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 0.141 · 95% CI 0.050 to 0.232
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.197 · 95% CI 0.106 to 0.288
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.249 · 95% CI 0.157 to 0.340
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.245 · 95% CI 0.155 to 0.336
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.348 · 95% CI 0.258 to 0.439
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.222 · Mean difference (final values): 0.056 · 95% CI -0.034 to 0.147
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.020 · Hazard ratio, log: 0.108 · 95% CI 0.017 to 0.199
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.022 · Mean difference (final values): 0.105 · 95% CI 0.015 to 0.195
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.262 · Mean difference (final values): 0.052 · 95% CI -0.039 to 0.143
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.290 · Mean difference (final values): 0.048 · 95% CI -0.041 to 0.138
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.938 · Mean difference (final values): -0.004 · 95% CI -0.094 to 0.087
SecondaryTime to Onset of Action (Change From Baseline in Post-dose FEV1 ≥ 100 mL) on Day 1

Time to onset of action is defined as the time (in minutes) from receiving the study drug on Day 1, until the FEV1 change from baseline is ≥100 mL.

Time frame:
Day 1
Reported as:
Mean · minutes
Time to Onset of Action (Change From Baseline in Post-dose FEV1 ≥ 100 mL) on Day 1
minutesTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Time to Onset of Action (Change From Baseline in Post-dose FEV1 ≥ 100 mL) on Day 145.1 (34.5 to 66.2)32.6 (30.7 to 45.6)29.5 (16.3 to 30.8)27.3 (16.5 to 30.5)240.1 (179.6 to 361.8)28.1 (18.0 to 32.1)
Statistical analysis
  • Treatment A vs Treatment E · Regression, Cox · p = 0.002 · Hazard ratio (hr): 1.64 · 95% CI 1.21 to 2.24
  • Treatment B vs Treatment E · Regression, Cox · p = <0.001 · Hazard ratio (hr): 2.18 · 95% CI 1.61 to 2.94
  • Treatment C vs Treatment E · Regression, Cox · p = <0.001 · Hazard ratio (hr): 2.79 · 95% CI 2.07 to 3.78
  • Treatment D vs Treatment E · Regression, Cox · p = <0.001 · Hazard ratio (hr): 3.07 · 95% CI 2.27 to 4.15
  • Treatment E vs Treatment F · Regression, Cox · p = <0.001 · Hazard ratio (hr): 3.10 · 95% CI 2.30 to 4.17
  • Treatment A vs Treatment B · Regression, Cox · p = 0.052 · Hazard ratio (hr): 1.32 · 95% CI 1.00 to 1.76
  • Treatment A vs Treatment C · Regression, Cox · p = <0.001 · Hazard ratio (hr): 1.70 · 95% CI 1.28 to 2.26
  • Treatment A vs Treatment D · Regression, Cox · p = <0.001 · Hazard ratio (hr): 1.87 · 95% CI 1.41 to 2.48
  • Treatment B vs Treatment C · Regression, Cox · p = 0.074 · Hazard ratio (hr): 1.28 · 95% CI 0.98 to 1.69
  • Treatment B vs Treatment D · Regression, Cox · p = 0.013 · Hazard ratio (hr): 1.41 · 95% CI 1.08 to 1.85
  • Treatment C vs Treatment D · Regression, Cox · p = 0.494 · Hazard ratio (hr): 1.10 · 95% CI 0.84 to 1.44
SecondaryNumber of Patients Achieving Onset of Action - Change From Baseline in Post-dose FEV1 ≥100 mL on Day 1

Number of patients achieving onset of action was defined as a change from baseline in post-dose FEV1 ≥100 mL on Day 1. These are the patients who contributed to the results, reported as median and 95% CI for 'time to onset of action' presented in Outcome Measure 8, above.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Patients Achieving Onset of Action - Change From Baseline in Post-dose FEV1 ≥100 mL on Day 1
ParticipantsTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Number of Patients Achieving Onset of Action - Change From Baseline in Post-dose FEV1 ≥100 mL on Day 19010310311074113
SecondaryChange From Baseline in Pre-dose Morning FEV1 at Week 3 and Week 6

Change from baseline in FEV1 at treatment visit 3 (Week 3) and treatment visit 4 (Week 6) of treatment. Spirometry, used to measure FEV1, was performed according to internationally accepted standards. Definitions: Baseline=Baseline value was the average of the pre-dose measurements (at 45 mins and 15 mins pre-dose), at Visit 2 (Week 0); FEV1=Forced expiratory volume in the 1st second;

Time frame:
Baseline, Week 3, Week 6
Reported as:
Least squares mean · Litres
Change From Baseline in Pre-dose Morning FEV1 at Week 3 and Week 6
LitresTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Week 30.059 (0.025 to 0.092)0.080 (0.047 to 0.114)0.122 (0.088 to 0.156)0.111 (0.078 to 0.145)0.000 (-0.034 to 0.034)0.122 (0.089 to 0.156)
Week 60.020 (-0.018 to 0.058)0.088 (0.050 to 0.126)0.107 (0.068 to 0.145)0.130 (0.093 to 0.168)-0.012 (-0.050 to 0.027)0.112 (0.074 to 0.150)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.017 · Mean difference (final values): 0.059 · 95% CI 0.011 to 0.107
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.001 · Mean difference (final values): 0.080 · 95% CI 0.032 to 0.128
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.122 · 95% CI 0.074 to 0.170
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Hazard ratio, log: 0.111 · 95% CI 0.063 to 0.159
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.122 · 95% CI 0.074 to 0.170
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.377 · Mean difference (final values): 0.021 · 95% CI -0.026 to 0.069
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.010 · Mean difference (final values): 0.063 · 95% CI 0.015 to 0.111
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.031 · Mean difference (final values): 0.052 · 95% CI 0.005 to 0.100
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.085 · Mean difference (final values): 0.042 · 95% CI -0.006 to 0.089
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.199 · Mean difference (final values): 0.031 · 95% CI -0.016 to 0.079
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.657 · Mean difference (final values): -0.011 · 95% CI -0.058 to 0.037
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.246 · Mean difference (final values): 0.032 · 95% CI -0.022 to 0.086
  • Treatment B vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.100 · 95% CI 0.046 to 0.154
  • Treatment C vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.119 · 95% CI 0.064 to 0.173
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.142 · 95% CI 0.088 to 0.196
  • Treatment E vs Treatment F · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.124 · 95% CI 0.070 to 0.178
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.014 · Mean difference (final values): 0.068 · 95% CI 0.014 to 0.121
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.002 · Mean difference (final values): 0.087 · 95% CI 0.032 to 0.141
  • Treatment A vs Treatment D · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 0.110 · 95% CI 0.057 to 0.163
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.493 · Mean difference (final values): 0.019 · 95% CI -0.035 to 0.073
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.119 · Mean difference (final values): 0.042 · 95% CI -0.011 to 0.096
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.392 · Mean difference (final values): 0.023 · 95% CI -0.030 to 0.077
SecondaryChange From Baseline in Pre-Dose Morning Inspiratory Capacity (IC) at Week 3 and Week 6

Change from baseline in IC at treatment Visit 3 (Week 3) and treatment Visit 4 (Week 6). Spirometry was used to measure IC and was performed according to internationally accepted standards. Definitions: Baseline: value of the measurement recorded at 45 mins pre-dose at Visit 2 (Week 0); IC=Inspiratory capacity;

Time frame:
Baseline, Week 3, Week 6
Reported as:
Least squares mean · Litres
Change From Baseline in Pre-Dose Morning Inspiratory Capacity (IC) at Week 3 and Week 6
LitresTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Week 30.156 (0.090 to 0.222)0.137 (0.071 to 0.203)0.106 (0.040 to 0.172)0.140 (0.074 to 0.205)0.047 (-0.020 to 0.113)0.090 (0.024 to 0.156)
Week 60.045 (-0.025 to 0.115)0.090 (0.021 to 0.160)0.136 (0.065 to 0.207)0.105 (0.036 to 0.174)0.025 (-0.046 to 0.096)0.099 (0.029 to 0.169)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.023 · Mean difference (final values): 0.109 · 95% CI 0.015 to 0.203
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.058 · Mean difference (final values): 0.090 · 95% CI -0.003 to 0.184
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.215 · Mean difference (final values): 0.059 · 95% CI -0.035 to 0.153
  • Treatment D vs Treatment E · Mixed Models Analysis · p = 0.051 · Mean difference (final values): 0.093 · 95% CI -0.001 to 0.187
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.364 · Mean difference (final values): 0.044 · 95% CI -0.051 to 0.138
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.694 · Mean difference (final values): -0.019 · 95% CI -0.112 to 0.074
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.297 · Mean difference (final values): -0.050 · 95% CI -0.143 to 0.044
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.734 · Mean difference (final values): -0.016 · 95% CI -0.109 to 0.077
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.514 · Mean difference (final values): -0.031 · 95% CI -0.124 to 0.062
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.957 · Mean difference (final values): 0.003 · 95% CI -0.090 to 0.095
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.479 · Mean difference (final values): 0.034 · 95% CI -0.060 to 0.127
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.687 · Mean difference (final values): 0.020 · 95% CI -0.079 to 0.120
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.195 · Mean difference (final values): 0.066 · 95% CI -0.034 to 0.165
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.030 · Mean difference (final values): 0.111 · 95% CI 0.011 to 0.212
  • Treatment D vs Treatment E · Mixed Models Analysis · p = 0.112 · Mean difference (final values): 0.080 · 95% CI -0.019 to 0.179
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.147 · Mean difference (final values): 0.074 · 95% CI -0.026 to 0.174
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.370 · Mean difference (final values): 0.045 · 95% CI -0.054 to 0.144
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.074 · Mean difference (final values): 0.091 · 95% CI -0.009 to 0.190
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.233 · Mean difference (final values): 0.060 · 95% CI -0.039 to 0.158
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.369 · Mean difference (final values): 0.046 · 95% CI -0.054 to 0.145
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.773 · Mean difference (final values): 0.014 · 95% CI -0.084 to 0.112
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.536 · Mean difference (final values): -0.031 · 95% CI -0.130 to 0.068
SecondaryTransition Dyspnea Index (TDI) Response (Focal Score ≥1) at Week 3 and Week 6

Number of subjects achieving TDI focal score ≥1, at treatment visit 3 (Week 3) and at treatment visit 4 (Week 6). TDI is a validated, interviewer-administered questionnaire that measures changes in dyspnea severity from the baseline established by the BDI questionnaire. TDI consists of the same 24 items and 3 domains as the BDI, with the same 2-week recall period. Each category is rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement); total score ranging from -9 to +9, with higher scores indicating better outcomes. The minimal clinically important differences (MCID) is considered a change of ≥1 unit. The same investigator or designee interviewed the subject for the BDI and TDI during the study period. A TDI focal score of ≥1 is considered as clinically important. Definitions: Baseline=The BDI focal score value at Visit 2 (Week 0); BDI=Baseline Dyspnea Index; MCID=Minimal Clinically Important Differences; TDI=Transition Dyspnea Index;

Time frame:
Baseline, Week 3, Week 6
Reported as:
Count of participants · Participants
Transition Dyspnea Index (TDI) Response (Focal Score ≥1) at Week 3 and Week 6
ParticipantsTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Week 3 Focal Score ≥ 1707875846774
Week 6 Focal Score ≥ 1748382915580
Statistical analysis
  • Treatment A vs Treatment E · Regression, Logistic · p = 0.848 · Odds ratio (or): 1.05 · 95% CI 0.62 to 1.77
  • Treatment B vs Treatment E · Regression, Logistic · p = 0.264 · Odds ratio (or): 1.35 · 95% CI 0.80 to 2.28
  • Treatment C vs Treatment E · Regression, Logistic · p = 0.343 · Odds ratio (or): 1.29 · 95% CI 0.76 to 2.18
  • Treatment D vs Treatment E · Regression, Logistic · p = 0.042 · Odds ratio (or): 1.74 · 95% CI 1.02 to 2.98
  • Treatment E vs Treatment F · Regression, Logistic · p = 0.503 · Odds ratio (or): 1.20 · 95% CI 0.71 to 2.02
  • Treatment A vs Treatment B · Regression, Logistic · p = 0.354 · Odds ratio (or): 1.28 · 95% CI 0.76 to 2.16
  • Treatment A vs Treatment C · Regression, Logistic · p = 0.447 · Odds ratio (or): 1.22 · 95% CI 0.73 to 2.07
  • Treatment A vs Treatment D · Regression, Logistic · p = 0.064 · Odds ratio (or): 1.66 · 95% CI 0.97 to 2.83
  • Treatment B vs Treatment C · Regression, Logistic · p = 0.867 · Odds ratio (or): 0.96 · 95% CI 0.57 to 1.62
  • Treatment B vs Treatment D · Regression, Logistic · p = 0.347 · Odds ratio (or): 1.29 · 95% CI 0.76 to 2.22
  • Treatment C vs Treatment D · Regression, Logistic · p = 0.269 · Odds ratio (or): 1.35 · 95% CI 0.79 to 2.32
  • Treatment A vs Treatment E · Regression, Logistic · p = 0.018 · Odds ratio (or): 1.92 · 95% CI 1.12 to 3.30
  • Treatment B vs Treatment E · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.59 · 95% CI 1.50 to 4.49
  • Treatment C vs Treatment E · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.08 · 95% CI 1.75 to 5.44
  • Treatment D vs Treatment E · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.42 · 95% CI 1.94 to 6.02
  • Treatment E vs Treatment F · Regression, Logistic · p = 0.001 · Odds ratio (or): 2.45 · 95% CI 1.41 to 4.26
  • Treatment A vs Treatment B · Regression, Logistic · p = 0.284 · Odds ratio (or): 1.35 · 95% CI 0.78 to 2.35
  • Treatment A vs Treatment C · Regression, Logistic · p = 0.103 · Odds ratio (or): 1.61 · 95% CI 0.91 to 2.84
  • Treatment A vs Treatment D · Regression, Logistic · p = 0.045 · Odds ratio (or): 1.78 · 95% CI 1.01 to 3.14
  • Treatment B vs Treatment C · Regression, Logistic · p = 0.557 · Odds ratio (or): 1.19 · 95% CI 0.67 to 2.12
  • Treatment B vs Treatment D · Regression, Logistic · p = 0.345 · Odds ratio (or): 1.32 · 95% CI 0.74 to 2.34
  • Treatment C vs Treatment D · Regression, Logistic · p = 0.732 · Odds ratio (or): 1.11 · 95% CI 0.61 to 2.00
SecondaryTransition Dyspnea Index (TDI) Focal Score at Week 3 and Week 6

Transitional Dyspnea Index (TDI) focal score at treatment visit 3 (Week 3) and treatment visit 4 (Week 6). TDI is a validated, interviewer-administered questionnaire that measures changes in dyspnea severity from the baseline established by the BDI questionnaire. TDI consists of the same 24 items and 3 domains as the BDI, with the same 2-week recall period. Each category is rated by 7 grades ranging from -3 (major deterioration) to +3 (major improvement), with a total score ranging from -9 to +9, with higher scores indicating better outcomes. The minimal clinically important differences (MCID) is considered a change of ≥1 unit. The same investigator or designee interviewed the subject for the BDI and TDI during the study period. A TDI focal score of ≥1 is considered as clinically important. Definitions: Baseline=The BDI focal score value at Visit 2 (Week 0); BDI=Baseline Dyspnea Index; MCID=Minimal Clinically Important Differences; TDI=Transition Dyspnea Index;

Time frame:
Baseline, Week 3, Week 6
Reported as:
Least squares mean · score on a scale
Transition Dyspnea Index (TDI) Focal Score at Week 3 and Week 6
score on a scaleTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Week 31.29 (0.82 to 1.75)1.55 (1.09 to 2.01)1.54 (1.07 to 2.01)1.94 (1.47 to 2.40)1.14 (0.67 to 1.61)1.66 (1.20 to 2.13)
Week 61.65 (1.18 to 2.11)2.02 (1.55 to 2.48)2.05 (1.58 to 2.52)2.55 (2.09 to 3.01)1.03 (0.56 to 1.51)2.11 (1.65 to 2.58)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.666 · Mean difference (final values): 0.15 · 95% CI -0.52 to 0.81
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.224 · Mean difference (final values): 0.41 · 95% CI -0.25 to 1.07
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.239 · Mean difference (final values): 0.40 · 95% CI -0.27 to 1.06
  • Treatment D vs Treatment E · Mixed Models Analysis · p = 0.019 · Mean difference (final values): 0.80 · 95% CI 0.13 to 1.46
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.124 · Mean difference (final values): 0.52 · 95% CI -0.14 to 1.19
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.432 · Mean difference (final values): 0.26 · 95% CI -0.39 to 0.92
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.454 · Mean difference (net): 0.25 · 95% CI -0.41 to 0.91
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.053 · Mean difference (final values): 0.65 · 95% CI -0.01 to 1.31
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.973 · Mean difference (final values): -0.01 · 95% CI -0.67 to 0.65
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.247 · Mean difference (final values): 0.39 · 95% CI -0.27 to 1.04
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.235 · Mean difference (final values): 0.40 · 95% CI -0.26 to 1.06
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.071 · Mean difference (final values): 0.61 · 95% CI -0.05 to 1.28
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.004 · Mean difference (final values): 0.98 · 95% CI 0.32 to 1.64
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 1.01 · 95% CI 0.35 to 1.68
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): 1.52 · 95% CI 0.86 to 2.18
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.002 · Mean difference (final values): 1.08 · 95% CI 0.41 to 1.75
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.271 · Mean difference (final values): 0.37 · 95% CI -0.29 to 1.03
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.235 · Mean difference (final values): 0.40 · 95% CI -0.26 to 1.06
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.007 · Mean difference (final values): 0.90 · 95% CI 0.25 to 1.56
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.923 · Mean difference (final values): 0.03 · 95% CI -0.63 to 0.69
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.108 · Mean difference (final values): 0.53 · 95% CI -0.12 to 1.19
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.134 · Mean difference (final values): 0.50 · 95% CI -0.16 to 1.16
SecondaryChange From Baseline in Percentage of Rescue Medication-Free Days During Inter-Visit Periods and the Entire Treatment Period

Evaluate the number of rescue medication-free days compared with baseline. Results are shown as percentage (%) of rescue medication-free days; an increased value indicates improvement from baseline. Definitions: Baseline=Data recorded during the run-in period (a 2-week period prior to randomization to study treatment and study drug intake); Inter-visit period 1=Starts at randomization to treatment (Visit 2, Week 0) and runs to the day before the subject returns to the clinic (Visit 3, Week 3); Inter-visit period 2=Starts when the subject returns to the clinic (Visit 3, Week 3) and runs to the end of the randomized treatment period (Visit 4, Week 6); Entire Treatment period=From day of randomization to drug intake to the end of the randomized treatment period (Visit 4, Week 6); Randomization=Randomization to study drug treatment (Visit 2, Week 0).

Time frame:
Baseline, Inter-visit period 1, Inter-visit period 2, Entire treatment period
Reported as:
Least squares mean · % of of rescue medication-free days
Change From Baseline in Percentage of Rescue Medication-Free Days During Inter-Visit Periods and the Entire Treatment Period
% of of rescue medication-free daysTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Inter-visit period 116.78 (12.02 to 21.54)15.67 (10.96 to 20.39)15.55 (10.79 to 20.31)18.19 (13.44 to 22.94)8.90 (4.12 to 13.68)13.51 (8.52 to 18.50)
Inter-visit period 213.83 (8.69 to 18.97)15.51 (10.40 to 20.62)14.03 (8.83 to 19.23)18.15 (13.04 to 23.27)7.07 (1.87 to 12.27)11.27 (5.85 to 16.69)
Entire treatment period15.30 (10.61 to 20.00)15.59 (10.93 to 20.25)14.79 (10.07 to 19.50)18.17 (13.49 to 22.86)7.98 (3.25 to 12.72)12.39 (7.45 to 17.32)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.022 · Mean difference (final values): 7.88 · 95% CI 1.13 to 14.63
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.048 · Mean difference (final values): 6.78 · 95% CI 0.07 to 13.48
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.053 · Mean difference (final values): 6.65 · 95% CI -0.09 to 13.40
  • Treatment D vs Treatment E · Mixed Models Analysis · p = 0.007 · Mean difference (final values): 9.29 · 95% CI 2.55 to 16.04
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.191 · Mean difference (final values): 4.61 · 95% CI -2.31 to 11.53
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.747 · Mean difference (final values): -1.10 · 95% CI -7.80 to 5.60
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.720 · Mean difference (final values): -1.23 · 95% CI -7.96 to 5.50
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.680 · Mean difference (final values): 1.41 · 95% CI -5.31 to 8.14
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.971 · Mean difference (final values): -0.12 · 95% CI -6.82 to 6.57
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.460 · Mean difference (final values): 2.52 · 95% CI -4.17 to 9.21
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.441 · Mean difference (final values): 2.64 · 95% CI -4.09 to 9.37
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.070 · Mean difference (final values): 6.76 · 95% CI -0.55 to 14.08
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.023 · Mean difference (final values): 8.44 · 95% CI 1.16 to 15.72
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.064 · Mean difference (final values): 6.96 · 95% CI -0.40 to 14.31
  • Treatment D vs Treatment E · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 11.08 · 95% CI 3.79 to 18.38
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.274 · Mean difference (final values): 4.20 · 95% CI -3.32 to 11.72
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.649 · Mean difference (final values): 1.68 · 95% CI -5.57 to 8.93
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.958 · Mean difference (final values): 0.20 · 95% CI -7.12 to 7.51
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.242 · Mean difference (final values): 4.32 · 95% CI -2.93 to 11.58
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.690 · Mean difference (final values): -1.48 · 95% CI -8.77 to 5.81
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.473 · Mean difference (final values): 2.64 · 95% CI -4.58 to 9.87
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.267 · Mean difference (final values): 4.13 · 95% CI -3.17 to 11.43
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.032 · Mean difference (final values): 7.32 · 95% CI 0.65 to 13.99
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.025 · Mean difference (final values): 7.61 · 95% CI 0.97 to 14.24
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.046 · Mean difference (final values): 6.80 · 95% CI 0.12 to 13.49
  • Treatment D vs Treatment E · Mixed Models Analysis · p = 0.003 · Mean difference (final values): 10.19 · 95% CI 3.52 to 16.85
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.207 · Mean difference (final values): 4.40 · 95% CI -2.45 to 11.25
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.932 · Mean difference (final values): 0.29 · 95% CI -6.33 to 6.91
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.879 · Mean difference (final values): -0.52 · 95% CI -7.17 to 6.14
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.396 · Mean difference (final values): 2.87 · 95% CI -3.77 to 9.50
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.812 · Mean difference (final values): -0.80 · 95% CI -7.44 to 5.83
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.444 · Mean difference (final values): 2.58 · 95% CI -4.03 to 9.19
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.319 · Mean difference (final values): 3.38 · 95% CI -3.27 to 10.04
SecondaryChange From Baseline in Average Use of Rescue Medication During Inter-Visit Periods and the Entire Treatment Period

Evaluate the change from baseline in average use of rescue medication (number of puffs/day) during the inter-visit periods and the entire treatment period. Results are shown as number of puffs/day; a decrease (implies improvement) from baseline in average use of rescue medication. Definitions: Baseline=Data recorded during the run-in period (a 2-week period prior to randomization to study treatment and study drug intake); Inter-visit period 1=Starts at randomization to treatment (Visit 2, Week 0) and runs to the day before the subject returns to the clinic (Visit 3 (Week 3); Inter-visit period 2=Starts when the subject returns to the clinic (Visit 3, Week 3) and runs to the end of the randomized treatment period (Visit 4, Week 6); Entire Treatment period=From day of randomization to drug intake to the end of the randomized treatment period (Visit 4, Week 6); Randomization=Randomization to study drug treatment (Visit 2, Week 0);

Time frame:
Baseline, Inter-visit period 1, Inter-visit period 2, Entire treatment period
Reported as:
Least squares mean · Number of puffs/day
Change From Baseline in Average Use of Rescue Medication During Inter-Visit Periods and the Entire Treatment Period
Number of puffs/dayTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Inter-visit period 1-0.72 (-0.90 to -0.55)-0.58 (-0.75 to -0.41)-0.53 (-0.70 to -0.35)-0.71 (-0.89 to -0.54)-0.30 (-0.47 to -0.12)-0.52 (-0.70 to -0.34)
Inter-visit period 2-0.59 (-0.78 to -0.39)-0.50 (-0.69 to -0.30)-0.51 (-0.71 to -0.31)-0.69 (-0.89 to -0.50)-0.17 (-0.37 to 0.03)-0.40 (-0.61 to -0.19)
Entire treatment period-0.66 (-0.83 to -0.48)-0.54 (-0.71 to -0.37)-0.52 (-0.70 to -0.34)-0.70 (-0.88 to -0.53)-0.23 (-0.41 to -0.06)-0.46 (-0.64 to -0.28)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.43 · 95% CI -0.67 to -0.18
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.023 · Mean difference (final values): -0.28 · 95% CI -0.53 to -0.04
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.067 · Mean difference (final values): -0.23 · 95% CI -0.47 to 0.02
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.42 · 95% CI -0.66 to -0.17
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.084 · Mean difference (final values): -0.22 · 95% CI -0.47 to 0.03
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.243 · Mean difference (final values): 0.14 · 95% CI -0.10 to 0.39
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.112 · Mean difference (final values): 0.20 · 95% CI -0.05 to 0.44
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.929 · Mean difference (final values): 0.01 · 95% CI -0.23 to 0.26
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.668 · Mean difference (final values): 0.05 · 95% CI -0.19 to 0.30
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.281 · Mean difference (final values): -0.13 · 95% CI -0.38 to 0.11
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.134 · Mean difference (final values): -0.19 · 95% CI -0.43 to 0.06
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -0.42 · 95% CI -0.70 to -0.14
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.020 · Mean difference (final values): -0.33 · 95% CI -0.61 to -0.05
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.017 · Mean difference (final values): -0.34 · 95% CI -0.62 to -0.06
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.52 · 95% CI -0.80 to -0.24
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.115 · Mean difference (final values): -0.23 · 95% CI -0.52 to 0.06
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.532 · Mean difference (final values): 0.09 · 95% CI -0.19 to 0.36
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.603 · Mean difference (final values): 0.07 · 95% CI -0.21 to 0.35
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.460 · Mean difference (final values): -0.10 · 95% CI -0.38 to 0.17
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.921 · Mean difference (final values): -0.01 · 95% CI -0.29 to 0.26
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.172 · Mean difference (final values): -0.19 · 95% CI -0.47 to 0.08
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.210 · Mean difference (final values): -0.18 · 95% CI -0.46 to 0.10
  • Treatment A vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.42 · 95% CI -0.67 to -0.17
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.016 · Mean difference (final values): -0.31 · 95% CI -0.55 to -0.06
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.025 · Mean difference (final values): -0.29 · 95% CI -0.54 to -0.04
  • Treatment D vs Treatment E · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.47 · 95% CI -0.72 to -0.22
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.083 · Mean difference (final values): -0.23 · 95% CI -0.48 to 0.03
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.355 · Mean difference (final values): 0.12 · 95% CI -0.13 to 0.36
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.283 · Mean difference (final values): 0.14 · 95% CI -0.11 to 0.38
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.712 · Mean difference (final values): -0.05 · 95% CI -0.29 to 0.20
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.877 · Mean difference (final values): 0.02 · 95% CI -0.23 to 0.27
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.195 · Mean difference (final values): -0.16 · 95% CI -0.41 to 0.08
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.150 · Mean difference (final values): -0.18 · 95% CI -0.43 to 0.07
SecondaryChange From Baseline in Average EXACT-Respiratory Symptom (E-RS) Total Score During Inter-Visit Periods and the Entire Treatment Period

Change from baseline in average EXACT-Respiratory Symptom (E-RS) total score during inter-visit periods and the entire treatment period E-RS in COPD uses 11 respiratory symptom items from the 14-item EXAcerbations of COPD tool (EXACT). E-RS total score quantifies respiratory symptom severity on a scale ranging from 0 to 40. Higher E-RS total scores indicate more severe symptoms and a declining total score indicates health improvement. E-RS questionnaire was completed by the patient each evening (e-diary). Definitions: For details on baseline, inter-visit periods, and the entire treatment period, please refer to outcome measure #15.

Time frame:
Baseline, Inter-visit period 1, Inter-visit period 2, Entire treatment period
Reported as:
Least squares mean · score on a scale
Change From Baseline in Average EXACT-Respiratory Symptom (E-RS) Total Score During Inter-Visit Periods and the Entire Treatment Period
score on a scaleTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
Inter-visit period 1-1.681 (-2.236 to -1.127)-1.539 (-2.087 to -0.990)-1.941 (-2.495 to -1.388)-1.663 (-2.215 to -1.111)-0.714 (-1.272 to -0.157)-1.280 (-1.862 to -0.698)
Inter-visit period 2-2.030 (-2.694 to -1.365)-1.840 (-2.499 to -1.180)-2.147 (-2.818 to -1.475)-2.077 (-2.737 to -1.417)-0.681 (-1.353 to -0.009)-1.505 (-2.206 to -0.803)
Entire treatment period-1.855 (-2.433 to -1.278)-1.689 (-2.262 to -1.116)-2.044 (-2.624 to -1.464)-1.870 (-2.445 to -1.295)-0.698 (-1.280 to -0.115)-1.393 (-2.001 to -0.784)
Statistical analysis
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.016 · Mean difference (final values): -0.967 · 95% CI -1.753 to -0.181
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.039 · Mean difference (final values): -0.824 · 95% CI -1.606 to -0.043
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -1.227 · 95% CI -2.012 to -0.441
  • Treatment D vs Treatment E · Mixed Models Analysis · p = 0.018 · Mean difference (final values): -0.949 · 95% CI -1.733 to -0.164
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.169 · Mean difference (final values): -0.566 · 95% CI -1.374 to 0.242
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.720 · Mean difference (final values): 0.142 · 95% CI -0.638 to 0.923
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.515 · Mean difference (final values): -0.260 · 95% CI -1.043 to 0.523
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.963 · Mean difference (final values): 0.018 · 95% CI -0.764 to 0.800
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.311 · Mean difference (final values): -0.402 · 95% CI -1.182 to 0.377
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.754 · Mean difference (final values): -0.124 · 95% CI -0.903 to 0.654
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.485 · Mean difference (final values): 0.278 · 95% CI -0.503 to 1.060
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.005 · Mean difference (final values): -1.349 · 95% CI -2.294 to -0.403
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.016 · Mean difference (final values): -1.159 · 95% CI -2.100 to -0.218
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -1.466 · 95% CI -2.416 to -0.516
  • Treatment D vs Treatment E · Mixed Models Analysis · p = 0.004 · Mean difference (final values): -1.396 · 95% CI -2.337 to -0.454
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.097 · Mean difference (final values): -0.824 · 95% CI -1.797 to 0.150
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.690 · Mean difference (final values): 0.190 · 95% CI -0.746 to 1.126
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.808 · Mean difference (final values): -0.117 · 95% CI -1.061 to 0.827
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.922 · Mean difference (final values): -0.047 · 95% CI -0.983 to 0.889
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.522 · Mean difference (final values): -0.307 · 95% CI -1.248 to 0.634
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.618 · Mean difference (final values): -0.237 · 95% CI -1.170 to 0.696
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.884 · Mean difference (final values): 0.070 · 95% CI -0.871 to 1.012
  • Treatment A vs Treatment E · Mixed Models Analysis · p = 0.006 · Mean difference (final values): -1.158 · 95% CI -1.978 to -0.337
  • Treatment B vs Treatment E · Mixed Models Analysis · p = 0.017 · Mean difference (final values): -0.992 · 95% CI -1.808 to -0.175
  • Treatment C vs Treatment E · Mixed Models Analysis · p = 0.001 · Mean difference (final values): -1.346 · 95% CI -2.168 to -0.524
  • Treatment D vs Treatment E · Mixed Models Analysis · p = 0.005 · Mean difference (final values): -1.172 · 95% CI -1.991 to -0.353
  • Treatment E vs Treatment F · Mixed Models Analysis · p = 0.107 · Mean difference (final values): -0.695 · 95% CI -1.539 to 0.149
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.689 · Mean difference (final values): 0.166 · 95% CI -0.648 to 0.980
  • Treatment A vs Treatment C · Mixed Models Analysis · p = 0.651 · Mean difference (final values): -0.188 · 95% CI -1.007 to 0.630
  • Treatment A vs Treatment D · Mixed Models Analysis · p = 0.973 · Mean difference (final values): -0.014 · 95% CI -0.830 to 0.801
  • Treatment B vs Treatment C · Mixed Models Analysis · p = 0.393 · Mean difference (final values): -0.355 · 95% CI -1.170 to 0.461
  • Treatment B vs Treatment D · Mixed Models Analysis · p = 0.663 · Mean difference (final values): -0.181 · 95% CI -0.993 to 0.632
  • Treatment C vs Treatment D · Mixed Models Analysis · p = 0.676 · Mean difference (final values): 0.174 · 95% CI -0.643 to 0.991
SecondaryVital Signs -- Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)

Vital signs -- Systolic blood pressure (SBP), Diastolic blood pressure (DBP) were measured at prespecified times, using a 12-Lead single ECGs were recorded at all study visits (pre-dose at V1 (Week -2) and V3 (Week 3), as well as at pre-dose and 1.5 hours post-dose at Visit 2 (Week 0) and Visit 4 (Week 6). Results are shown by treatment group, as change from baseline (in mmHg) for representative timepoints. Definitions: Baseline=Values recorded pre-dose (Visit 2, Week 0); Day 1=Day of the first dose of randomized study drug (Visit 2, Week 0);

Time frame:
Baseline, Day 1, Week 6
Reported as:
Mean · mmHg
Vital Signs -- Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)
mmHgTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
SBP, Day 1, 30 min post dose-1.4 (-31 to 25)-0.4 (-24 to 24)-2.0 (-31 to 24)-1.9 (-32 to 34)-0.9 (-25 to 26)-1.2 (-32 to 30)
DBP, Day 1, 30 min post dose-0.7 (-21 to 14)-0.6 (-15 to 15)-2.1 (-20 to 11)-1.4 (-28 to 17)-0.8 (-15 to 12)0.1 (-27 to 22)
SBP, Day 1, 1,5 h post dose0.3 (-33 to 24)-1.1 (-29 to 36)-0.6 (-33 to 24)-1.8 (-34 to 22)0.2 (-25 to 33)-1.5 (-30 to 34)
DBP, Day 1, 1,5 h post dose-0.7 (-20 to 17)-1.8 (-22 to 20)-1.7 (-23 to 13)-1.6 (-31 to 17)-1.7 (-18 to 14)-1.5 (-23 to 23)
SBP, Day 1, 11 h post dose1.1 (-27 to 34)2.0 (-25 to 39)-0.0 (-34 to 34)1.7 (-26 to 39)1.9 (-35 to 56)0.9 (-25 to 48)
DBP, Day 1, 11 h post dose-0.9 (-20 to 17)0.3 (-18 to 21)-1.6 (-27 to 17)-1.4 (-18 to 20)-1.0 (-25 to 22)-1.2 (-19 to 27)
SBP, Week 6, pre-dose0.4 (-34 to 31)0.8 (-50 to 34)0.4 (-27 to 47)-1.0 (-36 to 47)1.6 (-32 to 46)1.3 (-33 to 63)
DBP, Week 6, pre-dose0.4 (-32 to 25)0.5 (-23 to 21)-0.3 (-16 to 18)-1.0 (-28 to 25)0.0 (-26 to 18)-0.2 (-30 to 20)
SBP, Week 6, 30 min post dose-1.6 (-35 to 27)-0.9 (-62 to 39)-0.5 (-34 to 42)-2.5 (-41 to 35)0.5 (-30 to 42)0.1 (-35 to 54)
DBP, Week 6, 30 min post dose-0.7 (-24 to 21)-0.9 (-28 to 19)-1.5 (-24 to 19)-2.0 (-25 to 22)-0.8 (-24 to 24)-1.2 (-26 to 24)
SBP, Week 6, 1,5 h post dose-1.3 (-32 to 31)-0.6 (-31 to 36)-0.5 (-34 to 47)-2.3 (-42 to 40)0.1 (-34 to 49)0.5 (-34 to 67)
DBP, Week 6, 1,5 h post dose-1.0 (-28 to 21)-2.7 (-28 to 16)-2.0 (-21 to 17)-2.3 (-30 to 22)-1.1 (-31 to 19)-0.6 (-28 to 33)
SBP, Week 6, 11 h post dose0.2 (-38 to 36)1.5 (-26 to 36)0.5 (-31 to 53)2.2 (-37 to 53)3.2 (-25 to 66)2.0 (-26 to 45)
DBP, Week 6, 11 h post dose-0.9 (-24 to 21)-2.0 (-27 to 19)-2.3 (-25 to 25)-1.4 (-27 to 21)-1.0 (-27 to 20)-0.7 (-17 to 21)
SecondaryChange From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - Heart Rate (HR)

Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - Heart rate (HR) Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5m, +55m, and at +2.5 h.

Time frame:
Baseline, Day 1, Week 6
Reported as:
Mean · bpm
Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - Heart Rate (HR)
bpmTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
HR, Day 1, 5 min post dose-8.85 (-57.3 to 16.3)-6.62 (-53.7 to 22.3)-7.78 (-44.0 to 14.3)-7.64 (-41.3 to 19.0)-4.84 (-39.7 to 31.7)-5.54 (-34.3 to 24.3)
HR, Day 1, 55 min post dose-7.19 (-45.7 to 12.0)-8.29 (-33.3 to 10.3)-8.28 (-40.0 to 27.7)-9.59 (-74.0 to 17.3)-7.44 (-49.3 to 36.3)-7.19 (-41.3 to 37.7)
HR, Day 1, 2.5 h post dose-7.57 (-51.7 to 19.3)-6.75 (-51.0 to 16.7)-9.20 (-46.7 to 26.7)-7.46 (-94.7 to 21.0)-6.12 (-45.7 to 30.3)-8.96 (-40.0 to 18.0)
HR, Day before Week 6, 5 min post dose-1.72 (-56.3 to 34.3)-1.06 (-47.0 to 44.3)-1.61 (-37.0 to 30.3)-1.85 (-31.3 to 36.0)3.92 (-31.3 to 47.0)1.70 (-28.7 to 25.7)
HR, Day before Week 6, 55 min post dose-1.52 (-40.7 to 33.0)0.41 (-30.0 to 33.0)-1.10 (-37.3 to 49.3)-1.40 (-77.7 to 25.0)1.12 (-41.3 to 44.2)1.22 (-25.3 to 36.7)
HR, Day before Week 6, 2.5 h post dose-2.30 (-48.0 to 22.3)-0.01 (-58.3 to 44.3)-1.13 (-39.3 to 26.3)-0.73 (-42.0 to 39.7)2.49 (-35.7 to 43.7)-1.47 (-34.7 to 44.0)
SecondaryChange From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - PR Interval

Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - PR Interval Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values were recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.

Time frame:
Baseline, Day 1, Week 6
Reported as:
Mean · msec
Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - PR Interval
msecTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
PR Interval, Day 1, 5 min post dose7.24 (-23.0 to 54.7)6.53 (-17.3 to 48.3)6.08 (-36.0 to 37.3)6.71 (-14.3 to 41.7)3.06 (-20.7 to 33.7)4.90 (-18.3 to 30.7)
PR Interval, Day 1, 55 min post dose7.20 (-23.0 to 59.7)6.89 (-24.3 to 120.7)8.21 (-26.7 to 42.3)6.77 (-20.0 to 49.3)4.38 (-35.7 to 36.0)4.77 (-32.7 to 40.0)
PR Interval, Day 1, 2.5 h post dose8.48 (-20.3 to 77.7)9.38 (-37.0 to 131.3)7.58 (-18.7 to 91.3)6.16 (-22.0 to 47.3)5.84 (-27.0 to 38.7)4.25 (-36.7 to 40.7)
PR Interval, Day before Week 6, 5 min post dose0.44 (-27.7 to 39.3)1.36 (-30.0 to 59.0)-0.11 (-54.3 to 26.7)3.88 (-33.3 to 204.0)-1.36 (-48.3 to 31.7)0.82 (-23.3 to 37.2)
PR Interval, Day before Week 6, 55 min post dose0.88 (-47.3 to 32.3)2.37 (-53.7 to 38.7)1.91 (-76.3 to 37.7)0.82 (-33.3 to 50.0)-1.13 (-46.0 to 48.3)-1.66 (-48.0 to 25.0)
PR Interval, Day before Week 6, 2.5 h post dose2.50 (-38.7 to 40.0)3.01 (-54.7 to 76.0)0.16 (-59.0 to 81.0)0.84 (-30.0 to 61.7)-1.22 (-59.0 to 47.7)-1.94 (-47.0 to 55.3)
SecondaryChange From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - QRS Interval

Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - QRS Interval Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values were recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.

Time frame:
Baseline, Day 1, Week 6
Reported as:
Mean · msec
Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - QRS Interval
msecTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
QRS Interval, Day 1, 5 min post dose1.18 (-15.0 to 14.7)0.05 (-17.7 to 16.7)1.50 (-12.0 to 17.7)1.99 (-6.0 to 16.7)0.45 (-13.0 to 20.3)1.50 (-14.0 to 13.0)
QRS Interval, Day 1, 55 min post dose0.97 (-16.3 to 15.0)1.19 (-18.0 to 31.0)1.21 (-14.7 to 20.0)1.56 (-11.0 to 14.7)0.14 (-13.7 to 13.7)1.70 (-13.3 to 16.3)
QRS Interval, Day 1, 2.5 h post dose1.38 (-14.0 to 15.0)2.40 (-15.3 to 23.7)1.80 (-23.0 to 17.3)1.50 (-17.8 to 27.3)0.64 (-10.3 to 20.8)0.86 (-20.7 to 18.7)
QRS Interval, Day before Week 6, 5 min post dose0.61 (-23.3 to 34.0)-1.76 (-76.0 to 17.3)0.43 (-15.0 to 13.3)2.00 (-8.7 to 67.3)0.45 (-22.3 to 44.3)0.69 (-17.0 to 17.5)
QRS Interval, Day before Week 6, 55 min post dose1.12 (-10.7 to 29.3)-0.09 (-76.7 to 30.0)0.85 (-18.3 to 13.7)2.38 (-10.7 to 62.3)0.77 (-16.0 to 53.7)0.42 (-20.3 to 17.7)
QRS Interval, Day before Week 6, 2.5 h post dose1.49 (-14.0 to 40.0)0.74 (-73.0 to 25.0)0.30 (-18.3 to 24.0)2.18 (-18.2 to 59.3)1.14 (-14.7 to 43.7)1.35 (-15.7 to 27.0)
SecondaryChange From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - Fridericia-corrected QT Interval (QTcF)

Change from baseline in 24-Hour Holter electrocardiogram (ECG) parameters - Fridericia-corrected QT interval (QTcF). Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.

Time frame:
Baseline, Day 1, Week 6
Reported as:
Mean · msec
Change From Baseline in 24-Hour Holter Electrocardiogram (ECG) Parameters - Fridericia-corrected QT Interval (QTcF)
msecTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
QTcF, Day 1, 5 min post dose3.62 (-38.0 to 39.7)5.37 (-48.7 to 55.7)6.81 (-34.0 to 39.7)6.25 (-30.3 to 52.7)3.59 (-33.3 to 50.3)5.56 (-21.7 to 53.3)
QTcF, Day 1, 55 min post dose8.37 (-35.3 to 47.0)5.41 (-52.3 to 45.0)6.72 (-43.7 to 40.7)9.90 (-20.3 to 67.7)6.04 (-34.7 to 61.3)5.43 (-24.7 to 42.5)
QTcF, Day 1, 2.5 h post dose7.15 (-31.3 to 38.0)8.65 (-25.3 to 58.0)7.20 (-22.3 to 36.3)5.45 (-27.7 to 100.0)4.81 (-75.7 to 61.3)6.77 (-38.3 to 48.3)
QTcF, Day before Week 6, 5 min post dose1.61 (-44.3 to 35.7)1.14 (-70.7 to 76.3)-0.60 (-30.3 to 30.0)1.67 (-26.3 to 57.2)-3.56 (-40.0 to 26.7)1.41 (-26.7 to 58.0)
QTcF, Day before Week 6, 55 min post dose2.38 (-28.7 to 45.0)0.09 (-45.0 to 30.0)1.41 (-65.0 to 40.7)4.15 (-32.7 to 47.3)1.02 (-22.7 to 32.7)3.19 (-30.3 to 63.5)
QTcF, Day before Week 6, 2.5 h post dose4.13 (-32.7 to 40.7)0.85 (-64.0 to 51.7)-0.97 (-55.3 to 48.3)1.73 (-44.0 to 49.3)0.14 (-31.0 to 33.7)2.50 (-29.3 to 44.0)
Secondary24-hour Holter ECG - Prolonged QTcF - Male Subjects

24-hour Holter ECG - Prolonged QTcF - Male subjects. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.

Time frame:
Baseline, Day 1, Week 6
Reported as:
Count of participants · Participants
24-hour Holter ECG - Prolonged QTcF - Male Subjects
ParticipantsTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
QTcF, Day -1, 5 min — Actual value > 450 msec100121
QTcF, Day -1, 5 min — Actual value > 480 msec000000
QTcF, Day -1, 5 min — Actual value > 500 msec000000
QTcF, Day -1, 5 min — No prolongation (> 450 msec or > 480 msec or > 500 msec)625554576765
QTcF, Day -1, 55 min — Actual value > 450 msec111313
QTcF, Day -1, 55 min — Actual value > 480 msec000000
QTcF, Day -1, 55 min — Actual value > 500 msec000000
QTcF, Day -1, 55 min — No prolongation (> 450 msec or > 480 msec or > 500 msec)625453556863
QTcF, Day -1, 2.5 h — Actual value > 450 msec110220
QTcF, Day -1, 2.5 h — Actual value > 480 msec000010
QTcF, Day -1, 2.5 h — Actual value > 500 msec000000
QTcF, Day -1, 2.5 h — No prolongation (> 450 msec or > 480 msec or > 500 msec)625454566666
QTcF, Any post dose time point — Actual value > 450 msec346425
QTcF, Any post dose time point — Actual value > 480 msec101003
QTcF, Any post dose time point — Actual value > 500 msec000000
QTcF, Any post dose time point — No prolongation (> 450 msec or > 480 msec or > 500 msec)595147546758
QTcF, Day 1, 5 min post dose — Actual value > 450 msec223314
QTcF, Day 1, 5 min post dose — Actual value > 480 msec100001
QTcF, Day 1, 5 min post dose — Actual value > 500 msec000000
QTcF, Day 1, 5 min post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec)605351556861
QTcF, Day 1, 55 min post dose — Actual value > 450 msec223314
QTcF, Day 1, 55 min post dose — Actual value > 480 msec101001
QTcF, Day 1, 55 min post dose — Actual value > 500 msec000000
QTcF, Day 1, 55 min post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec)605350556861
QTcF, Day 1, 2.5 h post dose — Actual value > 450 msec333214
QTcF, Day 1, 2.5 h post dose — Actual value > 480 msec100000
QTcF, Day 1, 2.5 h post dose — Actual value > 500 msec000000
QTcF, Day 1, 2.5 h post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec)595251566862
QTcF, Day before Week 6, 5 min post dose — Actual value > 450 msec310302
QTcF, Day before Week 6, 5 min post dose — Actual value > 480 msec000001
QTcF, Day before Week 6, 5 min post dose — Actual value > 500 msec000000
QTcF, Day before Week 6, 5 min post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec)605454556963
QTcF, Day before Week 6, 55 min post dose — Actual value > 450 msec222203
QTcF, Day before Week 6, 55 min post dose — Actual value > 480 msec000001
QTcF, Day before Week 6, 55 min post dose — Actual value > 500 msec000000
QTcF, Day before Week 6, 55 min post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec)615352566962
QTcF, Day before Week 6, 2.5 h post dose — Actual value > 450 msec110103
QTcF, Day before Week 6, 2.5 h post dose — Actual value > 480 msec000000
QTcF, Day before Week 6, 2.5 h post dose — Actual value > 500 msec000000
QTcF, Day before Week 6, 2.5 h post dose — No prolongation (> 450 msec or > 480 msec or > 500 msec)625454576963
Secondary24-hour Holter ECG - Prolonged QTcF - Female Subjects

24-hour Holter ECG - Prolonged QTcF - Female subjects. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h.

Time frame:
Baseline, Day 1, Week 6
Reported as:
Count of participants · Participants
24-hour Holter ECG - Prolonged QTcF - Female Subjects
ParticipantsTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
QTcF, Day -1, 5 min — Actual value > 470 msec010000
QTcF, Day -1, 5 min — Actual value > 500 msec000000
QTcF, Day -1, 5 min — No prolongation (> 470 msec or > 500 msec)586767655257
QTcF, Day -1, 55 min — Actual value > 470 msec120100
QTcF, Day -1, 55 min — Actual value > 500 msec020000
QTcF, Day -1, 55 min — No prolongation (> 470 msec or > 500 msec)576467645257
QTcF, Day -1, 2.5 h — Actual value > 470 msec120000
QTcF, Day -1, 2.5 h — Actual value > 500 msec000000
QTcF, Day -1, 2.5 h — No prolongation (> 470 msec or > 500 msec)576667655257
QTcF, Any post dose time point — Actual value > 470 msec330101
QTcF, Any post dose time point — Actual value > 500 msec010000
QTcF, Any post dose time point — No prolongation (> 470 msec or > 500 msec)556467645256
QTcF, Day 1, 5 min post dose — Actual value > 470 msec120000
QTcF, Day 1, 5 min post dose — Actual value > 500 msec000000
QTcF, Day 1, 5 min post dose — No prolongation (> 470 msec or > 500 msec)576667655257
QTcF, Day 1, 55 min post dose — Actual value > 470 msec230000
QTcF, Day 1, 55 min post dose — Actual value > 500 msec000000
QTcF, Day 1, 55 min post dose — No prolongation (> 470 msec or > 500 msec)566567655257
QTcF, Day 1, 2.5 h post dose — Actual value > 470 msec120001
QTcF, Day 1, 2.5 h post dose — Actual value > 500 msec010000
QTcF, Day 1, 2.5 h post dose — No prolongation (> 470 msec or > 500 msec)576567655256
QTcF, Day before Week 6, 5 min post dose — Actual value > 470 msec120000
QTcF, Day before Week 6, 5 min post dose — Actual value > 500 msec000000
QTcF, Day before Week 6, 5 min post dose — No prolongation (> 470 msec or > 500 msec)576667655257
QTcF, Day before Week 6, 55 min post dose — Actual value > 470 msec020000
QTcF, Day before Week 6, 55 min post dose — Actual value > 500 msec000000
QTcF, Day before Week 6, 55 min post dose — No prolongation (> 470 msec or > 500 msec)586667655257
QTcF, Day before Week 6, 2.5 h post dose — Actual value > 470 msec010100
QTcF, Day before Week 6, 2.5 h post dose — Actual value > 500 msec000000
QTcF, Day before Week 6, 2.5 h post dose — No prolongation (> 470 msec or > 500 msec)586767645257
Secondary24-hour Holter ECG - Prolonged QTcF - Change From Baseline

24-hour Holter ECG - Prolonged QTcF - Change from baseline. Subjects had a 24-h Holter recording before and 24 h after the 1st dose of study drug (Visit 2) and for 24 h before the last dose of study drug (Visit 4). The time-matched values recorded during the 24 h before the 1st dose of study drug on Visit 2 and served as the baseline for the Holter-extracted ECG parameters. The time-averaged baseline score is the average of the Day -1 scores at +5 min, +55 min, and at +2.5 h. Results are presented as the number of subjects who had a change from baseline in QTcF of: \> 30 msec, \> 60 msec, and no prolongation (by \> 30 msec or \> 60 msec).

Time frame:
Baseline, Day 1, Week 6
Reported as:
Count of participants · Participants
24-hour Holter ECG - Prolonged QTcF - Change From Baseline
ParticipantsTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
QTcF, Any post dose time point — Change from baseline: > 30 msec192021201618
QTcF, Any post dose time point — Change from baseline: > 60 msec010221
QTcF, Any post dose time point — No change from baseline (> 30 msec or > 60 msec)102102100101103104
QTcF, Day 1, 5 min post dose — Change from baseline: > 30 msec249234
QTcF, Day 1, 5 min post dose — Change from baseline: > 60 msec000000
QTcF, Day 1, 5 min post dose — No change from baseline (> 30 msec or > 60 msec)119119112121118119
QTcF, Day 1, 55 min post dose — Change from baseline: > 30 msec845645
QTcF, Day 1, 55 min post dose — Change from baseline: > 60 msec000110
QTcF, Day 1, 55 min post dose — No change from baseline (> 30 msec or > 60 msec)113119116116116118
QTcF, Day 1, 2.5 h post dose — Change from baseline: > 30 msec5126568
QTcF, Day 1, 2.5 h post dose — Change from baseline: > 60 msec000110
QTcF, Day 1, 2.5 h post dose — No change from baseline (> 30 msec or > 60 msec)116111115117114115
QTcF, Day before Week 6, 5 min post dose — Change from baseline: > 30 msec530303
QTcF, Day before Week 6, 5 min post dose — Change from baseline: > 60 msec010000
QTcF, Day before Week 6, 5 min post dose — No change from baseline (> 30 msec or > 60 msec)116119121120121120
QTcF, Day before Week 6, 55 min post dose — Change from baseline: > 30 msec507734
QTcF, Day before Week 6, 55 min post dose — Change from baseline: > 60 msec000001
QTcF, Day before Week 6, 55 min post dose — No change from baseline (> 30 msec or > 60 msec)116123114116118118
QTcF, Day before Week 6, 2.5 h post dose — Change from baseline: > 30 msec663637
QTcF, Day before Week 6, 2.5 h post dose — Change from baseline: > 60 msec000000
QTcF, Day before Week 6, 2.5 h post dose — No change from baseline (> 30 msec or > 60 msec)115117118117118116

Adverse events

Collected over From the first intake of study medication (visit 2, Week 0) until study completion (Visit 4, week 6) or discontinuation.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/121 (0%)2/121 (1.7%)16/121 (13.2%)
Treatment B0/123 (0%)5/123 (4.1%)14/123 (11.4%)
Treatment C0/121 (0%)1/121 (0.8%)8/121 (6.6%)
Treatment D0/123 (0%)1/123 (0.8%)15/123 (12.2%)
Treatment E0/121 (0%)1/121 (0.8%)11/121 (9.1%)
Treatment F0/123 (0%)1/123 (0.8%)9/123 (7.3%)
Most frequent serious events
Most frequent serious events
EventTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
ConstipationGastrointestinal disorders1/1210/1230/1210/1230/1210/123
Prostate cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1210/1230/1210/1230/1210/123
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1211/1231/1210/1230/1210/123
HypertensionVascular disorders0/1210/1230/1210/1231/1210/123
InfluenzaInfections and infestations0/1210/1230/1211/1230/1210/123
Femur fractureInjury, poisoning and procedural complications0/1211/1230/1210/1230/1210/123
Spinal compression fractureInjury, poisoning and procedural complications0/1211/1230/1210/1230/1210/123
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1210/1230/1210/1230/1211/123
Cerebrovascular accidentNervous system disorders0/1211/1230/1210/1230/1210/123
NephrolithiasisRenal and urinary disorders0/1211/1230/1210/1230/1210/123
Most frequent other events
Most frequent other events
EventTreatment ATreatment BTreatment CTreatment DTreatment ETreatment F
HeadacheNervous system disorders5/1212/1231/1213/1232/1210/123
Upper respiratory tract infectionInfections and infestations4/1212/1232/1215/1232/1213/123
Viral upper respiratory tract infectionInfections and infestations0/1215/1231/1211/1233/1210/123
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/1210/1233/1214/1234/1214/123
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1211/1230/1211/1230/1212/123
BronchitisInfections and infestations1/1214/1231/1211/1230/1210/123

Baseline characteristics

Eligible patients male or female, aged ≥ 40 years with a diagnosis of COPD at least 12 months before the screening visit, who were current smokers or ex-smokers who had quit smoking at least 6 months prior to the screening visit, with a smoking history of at least 10 pack-years. Study inclusion and exclusion criteria are presented in the study protocol section.

Age, Continuous
Age, Continuous(years)Treatment ATreatment BTreatment CTreatment DTreatment ETreatment FTotal
Mean64.1 ± 9.1365.3 ± 9.1065.3 ± 8.1664.9 ± 9.1164.9 ± 9.2563.8 ± 9.5564.7 ± 9.05
Age, Customized
Age, Customized(Participants)Treatment ATreatment BTreatment CTreatment DTreatment ETreatment FTotal
< 65 years595356626062352
65-84 years606865605859370
> 85 years22013210
Sex: Female, Male
Sex: Female, Male(Participants)Treatment ATreatment BTreatment CTreatment DTreatment ETreatment FTotal
Female586867655257367
Male635554586966365
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment ATreatment BTreatment CTreatment DTreatment ETreatment FTotal
Hispanic or Latino7912115751
Not Hispanic or Latino114114109112115116680
Unknown or Not Reported0000101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment ATreatment BTreatment CTreatment DTreatment ETreatment FTotal
American Indian or Alaska Native0000202
Asian1000214
Native Hawaiian or Other Pacific Islander0000000
Black or African American13101014121069
White107110107108104110646
More than one race0000000
Unknown or Not Reported03411211
Region of Enrollment
Region of Enrollment(Participants)Treatment ATreatment BTreatment CTreatment DTreatment ETreatment FTotal
United States121123121123121123732
Weight
Weight(kg)Treatment ATreatment BTreatment CTreatment DTreatment ETreatment FTotal
Mean81.81 ± 20.6483.82 ± 19.3382.12 ± 22.7084.23 ± 22.4184.43 ± 21.8280.67 ± 17.4082.85 ± 20.77
Height
Height(cm)Treatment ATreatment BTreatment CTreatment DTreatment ETreatment FTotal
Mean168.95 ± 8.76169.38 ± 9.74169.21 ± 9.67168.17 ± 9.57169.34 ± 9.56169.53 ± 9.67169.10 ± 9.48

12 further baseline measures are reported on the registry.

08

Study locations

112 sites
  • Chiesi Investigational Site
    Birmingham, Alabama 35244, United States
  • Chiesi Investigational Site
    Dothan, Alabama 36305, United States
  • Chiesi Investigational Site
    Montgomery, Alabama 36106, United States
  • Chiesi Investigational Site
    Flagstaff, Arizona 86001, United States
  • Chiesi Investigational Site
    Glendale, Arizona 85306, United States
  • Chiesi Investigational Site
    Phoenix, Arizona 85006, United States
  • Chiesi Investigational Site
    Phoenix, Arizona 85014, United States
  • Chiesi Investigational Site
    Phoenix, Arizona 85018, United States
  • Chiesi Investigational Site
    Surprise, Arizona 85374, United States
  • Chiesi Investigational Site
    Tempe, Arizona 85283, United States
  • Chiesi Investigational Site
    Tucson, Arizona 85710, United States
  • Chiesi Investigational Site
    Anaheim, California 92801, United States
  • Chiesi Investigational Site
    Escondido, California 92025, United States
  • Chiesi Investigational Site
    Fullerton, California 92835, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Chiesi Investigational Site
    Long Beach, California 90806, United States
  • Chiesi Investigational Site
    Los Angeles, California 90017, United States
  • Chiesi Investigational Site
    Los Angeles, California 90036, United States
  • Chiesi Investigational Site
    Los Angeles, California 90048, United States
  • Chiesi Investigational Site
    Newport Beach, California 92663, United States
  • Chiesi Investigational Site
    San Diego, California 92120, United States
  • Chiesi Investigational Site
    Tustin, California 92780, United States
  • Chiesi Investigational Site
    Westminster, California 92683, United States
  • Chiesi Investigational Site
    Boulder, Colorado 80301, United States
  • Chiesi Investigational Site
    Centennial, Colorado 80112, United States
  • Chiesi Investigational Site
    Denver, Colorado 80230, United States
  • Chiesi Investigational Site
    Lafayette, Colorado 80026, United States
  • Chiesi Investigational Site
    Brandon, Florida 33511, United States
  • Chiesi Investigational Site
    Clearwater, Florida 33765, United States
  • Chiesi Investigational Site
    Daytona Beach, Florida 32117, United States
  • Chiesi Investigational Site
    Edgewater, Florida 32132, United States
  • Chiesi Investigational Site
    Hialeah, Florida 33012, United States
  • Chiesi Investigational Site
    Kissimmee, Florida 34741, United States
  • Chiesi Investigational Site
    Miami, Florida 33144, United States
  • Chiesi Investigational Site
    Miami, Florida 33165, United States
  • Chiesi Investigational Site
    Miami, Florida 33176, United States
  • Chiesi Investigational Site
    Miami, Florida 33186, United States
  • Chiesi Investigational Site
    Orlando, Florida 32825, United States
  • Chiesi Investigational Site
    Panama City, Florida 32405, United States
  • Chiesi Investigational Site
    Blue Ridge, Georgia 30513, United States
  • Chiesi Investigational Site
    Dacula, Georgia 30019, United States
  • Chiesi Investigational Site
    Duluth, Georgia 30096, United States
  • Chiesi Investigational Site
    Lawrenceville, Georgia 30046, United States
  • Chiesi Investigational Site
    Marietta, Georgia 30060, United States
  • Chiesi Investigational Site
    Savannah, Georgia 31405, United States
  • Chiesi Investigational Site
    Chicago, Illinois 60607, United States
  • Chiesi Investigational Site
    Evansville, Indiana 47714, United States
  • Chiesi Investigational Site
    Valparaiso, Indiana 46383, United States
  • Chiesi Investigational Site
    Louisville, Kentucky 40215, United States
  • Chiesi Investigational Site
    Louisville, Kentucky 40218, United States
  • Chiesi Investigational Site
    Crowley, Louisiana 70526, United States
  • Chiesi Investigational Site
    Lake Charles, Louisiana 70601, United States
  • Chiesi Investigational Site
    Lutherville, Maryland 21093, United States
  • Chiesi Investigational Site
    Fall River, Massachusetts 02720, United States
  • Chiesi Investigational Site
    Fall River, Massachusetts 02721, United States
  • Chiesi Investigational Site
    Ann Arbor, Michigan 48106, United States
  • Chiesi Investigational Site
    Farmington Hills, Michigan 48336, United States
  • Chiesi Investigational Site
    Minneapolis, Minnesota 55402, United States
  • Chiesi Investigational Site
    Saint Charles, Missouri 63301, United States
  • Chiesi Investigational Site
    Saint Louis, Missouri 63141, United States
  • Chiesi Investigational Site
    Missoula, Montana 59808, United States
  • Chiesi Investigational Site
    Omaha, Nebraska 68114, United States
  • Chiesi Investigational Site
    Las Vegas, Nevada 89119, United States
  • Chiesi Investigational Site
    Summit, New Jersey 07901, United States
  • Chiesi Investigational Site
    Albuquerque, New Mexico 87108, United States
  • Chiesi Investigational Site
    Bronx, New York 10455, United States
  • Chiesi Investigational Site
    Charlotte, North Carolina 28207, United States
  • Chiesi Investigational Site
    Gastonia, North Carolina 28054, United States
  • Chiesi Investigational Site
    Hendersonville, North Carolina 28739, United States
  • Chiesi Investigational Site
    Mooresville, North Carolina 28117, United States
  • Chiesi Investigational Site
    Raleigh, North Carolina 27607, United States
  • Chiesi Investigational Site
    Shelby, North Carolina 28150, United States
  • Chiesi Investigational Site
    Wilmington, North Carolina 28401, United States
  • Chiesi Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Chiesi Investigational Site
    Cincinnati, Ohio 45242, United States
  • Chiesi Investigational Site
    Columbus, Ohio 43213, United States
  • Chiesi Investigational Site
    Columbus, Ohio 43215, United States
  • Clinical Research Solutions
    Dayton, Ohio 45409, United States
  • Chiesi Investigational Site
    Grove City, Ohio 43123, United States
  • Chiesi Investigational Site
    Edmond, Oklahoma 73034, United States
  • Chiesi Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • Chiesi Investigational Site
    Medford, Oregon 97504, United States
  • Chiesi Investigational Site
    Portland, Oregon 97202, United States
  • Chiesi Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • Chiesi Investigational Site
    East Providence, Rhode Island 02914, United States
  • Chiesi Investigational Site
    Anderson, South Carolina 29621, United States
  • Chiesi Investigational Site
    Charleston, South Carolina 29406, United States
  • Chiesi Investigational Site
    Easley, South Carolina 29640, United States
  • Chiesi Investigational Site
    Fort Mill, South Carolina 29707, United States
  • Chiesi Investigational Site
    Gaffney, South Carolina 29340, United States
  • Chiesi Investigational Site
    Greenville, South Carolina 29615, United States
  • Chiesi Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • Chiesi Investigational Site
    Orangeburg, South Carolina 29118, United States
  • Chiesi Investigational Site
    Rock Hill, South Carolina 29732, United States
  • Chiesi Investigational Site
    Seneca, South Carolina 29678, United States
  • Chiesi Investigational Site
    Spartanburg, South Carolina 29303, United States
  • Chiesi Investigational Site
    Union, South Carolina 29379, United States
  • Chiesi Investigational Site
    Rapid City, South Dakota 57702, United States
  • Chiesi Investigational Site
    Franklin, Tennessee 37067, United States
  • Chiesi Investigational Site
    Jackson, Tennessee 38305, United States

Showing the first 100 of 112 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0. Erratum In: Lancet. 2013 Feb 23;381(9867):628. AlMazroa, Mohammad A [added]; Memish, Ziad A [added]. PubMed 23245604 ↗
  • Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010. Respir Res. 2013 Oct 9;14(1):103. doi: 10.1186/1465-9921-14-103. PubMed 24107140 ↗
  • Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002 May;121(5 Suppl):121S-126S. doi: 10.1378/chest.121.5_suppl.121s. PubMed 12010839 ↗
  • Tonnesen P. Smoking cessation and COPD. Eur Respir Rev. 2013 Mar 1;22(127):37-43. doi: 10.1183/09059180.00007212. PubMed 23457163 ↗
  • van Eerd EA, van der Meer RM, van Schayck OC, Kotz D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Aug 20;2016(8):CD010744. doi: 10.1002/14651858.CD010744.pub2. PubMed 27545342 ↗
  • Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 Oct 15;2013(10):CD010177. doi: 10.1002/14651858.CD010177.pub2. PubMed 24127118 ↗
  • McGarvey L, Niewoehner D, Magder S, Sachs P, Tetzlaff K, Hamilton A, Korducki L, Bothner U, Vogelmeier C, Koch A, Ferguson GT. One-Year Safety of Olodaterol Once Daily via Respimat(R) in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis. COPD. 2015;12(5):484-93. doi: 10.3109/15412555.2014.991864. Epub 2015 Feb 18. PubMed 25692310 ↗
  • Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010 Jun;65(6):473-9. doi: 10.1136/thx.2009.125435. PubMed 20522841 ↗
  • Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012 Jan 22;72(2):273-300. doi: 10.2165/11208620-000000000-00000. PubMed 22217233 ↗
  • Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005 Mar;127(3):809-17. doi: 10.1378/chest.127.3.809. PubMed 15764761 ↗
  • Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis. 2008;3(1):127-36. doi: 10.2147/copd.s2389. PubMed 18488436 ↗
  • Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Jul 11;(7):CD009285. doi: 10.1002/14651858.CD009285.pub2. PubMed 22786525 ↗
  • D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011 Dec 7;12(1):156. doi: 10.1186/1465-9921-12-156. PubMed 22151296 ↗
  • Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J. 2012 Nov;40(5):1106-14. doi: 10.1183/09031936.00040712. Epub 2012 Jul 26. PubMed 23060624 ↗
  • Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503-13. doi: 10.2147/COPD.S32451. Epub 2012 Jul 31. PubMed 22973092 ↗
  • Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:729-41. doi: 10.2147/COPD.S36001. Epub 2012 Oct 26. Erratum In: Int J Chron Obstruct Pulmon Dis. 2014;9:287. PubMed 23118536 ↗
  • Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002 Aug 1;166(3):333-9. doi: 10.1164/rccm.2110093. PubMed 12153966 ↗
  • Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium--the FDA's conclusions. N Engl J Med. 2010 Sep 16;363(12):1097-9. doi: 10.1056/NEJMp1008502. Epub 2010 Sep 8. No abstract available. PubMed 20843240 ↗
  • Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5. PubMed 18836213 ↗
  • Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. PubMed 27181606 ↗
  • Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD002991. doi: 10.1002/14651858.CD002991.pub2. PubMed 17443520 ↗
  • Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Mar 10;2014(3):CD010115. doi: 10.1002/14651858.CD010115.pub2. PubMed 24615270 ↗
  • Yawn BP, Li Y, Tian H, Zhang J, Arcona S, Kahler KH. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis. 2013;8:295-304. doi: 10.2147/COPD.S42366. Epub 2013 Jun 27. PubMed 23836970 ↗
  • Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol. 2007 Mar;98(3):225-38. doi: 10.1016/S1081-1206(10)60711-9. PubMed 17378253 ↗
  • Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004 Jul;126(1):213-9. doi: 10.1378/chest.126.1.213. PubMed 15249465 ↗
  • Tashkin DP, Murray HE, Skeans M, Murray RP. Skin manifestations of inhaled corticosteroids in COPD patients: results from Lung Health Study II. Chest. 2004 Oct;126(4):1123-33. doi: 10.1016/S0012-3692(15)31287-3. PubMed 15486373 ↗
  • Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009 Sep;34(3):641-7. doi: 10.1183/09031936.00193908. Epub 2009 May 14. PubMed 19443528 ↗
  • Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan;12(1):27-34. doi: 10.1513/AnnalsATS.201409-413OC. PubMed 25490706 ↗
  • Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med. 2016 Sep;4(9):731-741. doi: 10.1016/S2213-2600(16)30148-5. Epub 2016 Jul 23. PubMed 27460163 ↗
  • Johnell O, Pauwels R, Lofdahl CG, Laitinen LA, Postma DS, Pride NB, Ohlsson SV. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J. 2002 Jun;19(6):1058-63. doi: 10.1183/09031936.02.00276602. PubMed 12108857 ↗
  • Ferguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009 Dec;136(6):1456-1465. doi: 10.1378/chest.08-3016. Epub 2009 Jul 6. PubMed 19581353 ↗
  • Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011 Aug;66(8):699-708. doi: 10.1136/thx.2011.160028. Epub 2011 May 20. PubMed 21602540 ↗
  • Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010 Nov;123(11):1001-6. doi: 10.1016/j.amjmed.2010.06.019. Epub 2010 Oct 1. PubMed 20870201 ↗
  • Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009 Apr;116(4):652-7. doi: 10.1016/j.ophtha.2008.12.001. Epub 2009 Feb 25. PubMed 19243828 ↗
  • Miller DP, Watkins SE, Sampson T, Davis KJ. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Int J Chron Obstruct Pulmon Dis. 2011;6:467-76. doi: 10.2147/COPD.S14247. Epub 2011 Sep 16. PubMed 22003292 ↗
  • Andrejak C, Nielsen R, Thomsen VO, Duhaut P, Sorensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013 Mar;68(3):256-62. doi: 10.1136/thoraxjnl-2012-201772. Epub 2012 Jul 10. PubMed 22781123 ↗
  • Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K, Zamel N, FitzGerald M; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007 Apr 17;146(8):545-55. doi: 10.7326/0003-4819-146-8-200704170-00152. Epub 2007 Feb 19. PubMed 17310045 ↗
  • Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008 Jul;63(7):592-8. doi: 10.1136/thx.2007.087213. Epub 2008 Feb 1. PubMed 18245142 ↗
  • Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan;106(1):91-101. doi: 10.1016/j.rmed.2011.09.002. Epub 2011 Oct 29. PubMed 22040533 ↗
  • Frith PA, Thompson PJ, Ratnavadivel R, Chang CL, Bremner P, Day P, Frenzel C, Kurstjens N; Glisten Study Group. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015 Jun;70(6):519-27. doi: 10.1136/thoraxjnl-2014-206670. Epub 2015 Apr 3. PubMed 25841237 ↗
  • Siler TM, Kerwin E, Singletary K, Brooks J, Church A. Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies. COPD. 2016;13(1):1-10. doi: 10.3109/15412555.2015.1034256. Epub 2015 Oct 9. PubMed 26451734 ↗
  • Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1. PubMed 27598678 ↗
  • Chiesi Farmaceutici S.p.A. Randomised, double-blind, placebo-controlled, cross-over study to investigate the bronchodilator efficacy and safety after single and repeated administrations of different doses of glycopyrrolate via pMDI in moderate to severe COPD patients (GLYCO2). 2012 Jul 19; CCD-0916-CSR-0054.
  • Novartis Pharmaceuticals Corporation. SEEBRI™ NEOHALER® US Prescribing Information. East Hanover, New Jersey; 2016 Jan.
  • Boehringer Ingelheim Pharmaceuticals, Inc. SPIRIVA® HALER® US Prescribing Information. Ridgefield, Connecticut; 2016 Jan.
  • Arievich H, Overend T, Renard D, Gibbs M, Alagappan V, Looby M, Banerji D. A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med. 2012 Dec 8;12:74. doi: 10.1186/1471-2466-12-74. PubMed 23217058 ↗
  • LaForce C, Feldman G, Spangenthal S, Eckert JH, Henley M, Patalano F, D'Andrea P. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study. Int J Chron Obstruct Pulmon Dis. 2016 Jun 8;11:1233-43. doi: 10.2147/COPD.S100445. eCollection 2016. PubMed 27354782 ↗
  • Kerwin E, Siler TM, Korenblat P, White A, Eckert JH, Henley M, Patalano F, D'Andrea P. Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study. Chronic Obstr Pulm Dis. 2016 Mar 28;3(2):549-559. doi: 10.15326/jcopdf.3.2.2015.0157. PubMed 28848879 ↗
  • Chiesi Farmaceutici S.p.A. A multinational, multicentre, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy and safety of glycopyrrolate bromide administered via pMDI (CHF 5259), for the treatment of patients with chronic obstructive pulmonary disease. 2015 Nov 05; CCD-05993AA1-09.
  • Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, Lloyd M, Patalano F, Banerji D. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015 Nov 1;192(9):1068-79. doi: 10.1164/rccm.201505-1048OC. PubMed 26177074 ↗
  • Mahler DA, Gifford AH, Satti A, Jessop N, Eckert JH, D'Andrea P, Mota F, Banerjee R. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3). Respir Med. 2016 Jun;115:39-45. doi: 10.1016/j.rmed.2016.03.015. Epub 2016 Mar 22. PubMed 27215502 ↗
  • Sharafkhaneh A, Majid H, Gross NJ. Safety and tolerability of inhalational anticholinergics in COPD. Drug Healthc Patient Saf. 2013;5:49-55. doi: 10.2147/DHPS.S7771. Epub 2013 Mar 8. PubMed 23526112 ↗
  • Chiesi Farmaceutici S.p.A. A multicentre, randomised, double-blind, active-controlled, 4-way cross-over study to evaluate the efficacy and safety of a free combination of 3 doses of glycopyrrolate with fixed combination beclomethasone dipropionate plus formoterol (FOSTER®) in a metered dose inhaler for the treatment of patients with chronic obstructive pulmonary disease (COPD). 2013 May 16; CCD-1106-PR-0066.
  • Chiesi Farmaceutici S.p.A. Randomized, double-blind, active controlled, 3-arm parallel group, multi-national, multi-centre study to evaluate the cardiac safety of two doses of glycopyrrolate bromide (25µg and 50µg BID) delivered via HFA pMDI both combined with FOSTER® 100/6µg BID delivered via HFA pMDI versus FOSTER® 100/6µg BID delivered via HFA pMDI in patients with moderate to severe COPD. 2012 Jan 10; CCD-1107-PR-0067.
  • Rennard S, Fogarty C, Reisner C, Fernandez C, Fischer T, Golden M, Rose ES, Darken P, Tardie G, Orevillo C. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2014 Jul 16;14:118. doi: 10.1186/1471-2466-14-118. PubMed 25027304 ↗
  • Teva Respiratory LLC. QVAR® US Prescribing Information. Horsham, Pennsylvania; 2014 Jul.
  • Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984 Jun;85(6):751-8. doi: 10.1378/chest.85.6.751. PubMed 6723384 ↗
  • Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003 Feb;21(2):267-72. doi: 10.1183/09031936.03.00068503a. PubMed 12608440 ↗
  • Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509. PubMed 19720809 ↗
  • Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT) scores. BMC Pulm Med. 2011 Aug 11;11:42. doi: 10.1186/1471-2466-11-42. PubMed 21835018 ↗
  • Ellepola AN, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis. 2001 Jul;7(4):211-6. PubMed 11575870 ↗
  • Torres SR, Peixoto CB, Caldas DM, Silva EB, Akiti T, Nucci M, de Uzeda M. Relationship between salivary flow rates and Candida counts in subjects with xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Feb;93(2):149-54. doi: 10.1067/moe.2002.119738. PubMed 11862202 ↗
  • Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available. PubMed 16055882 ↗
  • Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest. 2010 Jan;137(1):138-45. doi: 10.1378/chest.09-0919. Epub 2009 Sep 9. PubMed 19741060 ↗
  • Hankinson JL, Bang KM. Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population. Am Rev Respir Dis. 1991 Mar;143(3):516-21. doi: 10.1164/ajrccm/143.3.516. PubMed 2001060 ↗
  • Boehringer Ingelheim Pharmaceuticals, Inc. ATROVENT® HFA US Prescribing Information. Ridgefield, Connecticut; 2012 Aug.
  • Taylor J, Kotch A, Rice K, Ghafouri M, Kurland CL, Fagan NM, Witek TJ Jr; Ipratropium Bromide HFA Study Group. Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. Chest. 2001 Oct;120(4):1253-61. doi: 10.1378/chest.120.4.1253. PubMed 11591569 ↗
  • Singh D, Zhu CQ, Sharma S, Church A, Kalberg CJ. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study. Pulm Pharmacol Ther. 2015 Apr;31:85-91. doi: 10.1016/j.pupt.2014.08.010. Epub 2014 Sep 6. PubMed 25197005 ↗
  • Beier J, van Noord J, Deans A, Brooks J, Maden C, Baggen S, Mehta R, Cahn A. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients. Int J Chron Obstruct Pulmon Dis. 2012;7:153-64. doi: 10.2147/COPD.S26100. Epub 2012 Mar 5. PubMed 22419863 ↗
  • Leidy NK, Sexton CC, Jones PW, Notte SM, Monz BU, Nelsen L, Goldman M, Murray LT, Sethi S. Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax. 2014 May;69(5):443-9. doi: 10.1136/thoraxjnl-2013-204428. Epub 2014 Mar 4. PubMed 24595666 ↗
  • Leidy NK, Murray LT, Monz BU, Nelsen L, Goldman M, Jones PW, Dansie EJ, Sethi S. Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014 Oct 7;15(1):124. doi: 10.1186/s12931-014-0124-z. PubMed 25287629 ↗
  • Evidera. E-RS (EXACT-Respiratory Symptoms) User Manual (Version 3.0). Bethesda, Maryland; 2014 Oct.
  • European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). c2012 Jun 21; EMA/CHMP/483572/2012.
  • Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005 Mar;2(1):111-24. doi: 10.1081/copd-200053377. PubMed 17136971 ↗
  • Mallinckrodt C, Roger J, Chuang-stein C, Molenberghs G, Lane PW, O'Kelly M, et al. Missing data: turning guidance into action. Stat Biopharm Res. 2013;5(4):369-82.
  • Mallinckrodt CH, Kenward MG. Conceptual Considerations regarding Endpoints, Hypotheses, and Analyses for Incomplete Longitudinal Clinical Trial Data. Drug Inf J. 2009; 43(4): 449-58.
  • National Research Council (US) Panel on Handling Missing Data in Clinical Trials. The Prevention and Treatment of Missing Data in Clinical Trials. Washington (DC): National Academies Press (US); 2010. Available from http://www.ncbi.nlm.nih.gov/books/NBK209904/ PubMed 24983040 ↗
  • Leuchs AK, Zinserling J, Brandt A, Wirtz D, Benda N. Choosing Appropriate Estimands in Clinical Trials. Ther Innov Regul Sci. 2015 Jul;49(4):584-592. doi: 10.1177/2168479014567317. PubMed 30222440 ↗
  • Edwards D, Berry JJ. The efficiency of simulation-based multiple comparisons. Biometrics. 1987 Dec;43(4):913-28. PubMed 3427176 ↗
  • Kerwin E, Feldman G, Pearle J, De La Cruz L, Edwards M, Beaudot C, Georges G. Efficacy and Safety of Inhaled Glycopyrronium Bromide in COPD: A Randomized, Parallel Group, Dose-Ranging Study (GLIMMER). COPD. 2021 Apr;18(2):181-190. doi: 10.1080/15412555.2021.1894111. Epub 2021 Mar 12. PubMed 33709856 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in May 2018, 9 months.

Results were first posted in Jun 2021, 3 years after primary completion. A results delay was requested in May 2019.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 9 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2017
First posted
Mar 21, 2017
StartActual
Jul 28, 2017
Primary completionActual
May 23, 2018
CompletionActual
Jun 6, 2018
Results delay requested
May 7, 2019
Results first posted
Jun 15, 2021
Last update
Jun 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03084796
Responsible party
Sponsor
First posted
Mar 21, 2017
Start date
Jul 28, 2017
Primary completion
May 23, 2018
Completion
Jun 6, 2018
Results posted
Jun 15, 2021
Last update
Jun 15, 2021

Study contacts

Edward Kerwin, MD
principal investigator · Crisor LLC c/o Clinical Research Institute of Southern Oregon, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion